

Bendamustine plus rituximab versus CHOP plus rituximab in
patients with indolent and mantle-cell lymphomas: an open-label
phase 3 non-inferiority trial

Lancet, The

381, 1203-1210

DOI: [10.1016/s0140-6736\(12\)61763-2](https://doi.org/10.1016/s0140-6736(12)61763-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Optimal Management of Follicular Lymphoma: An Evolving Field. <i>Drugs</i> , 2013, 73, 1395-1403.	4.9	6
2	Management of Mantle Cell Lymphoma in the Elderly: Current and Potential Strategies. <i>Drugs and Aging</i> , 2013, 30, 979-986.	1.3	3
3	Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. <i>American Journal of Hematology</i> , 2013, 88, 1082-1088.	2.0	180
4	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e548-e561.	5.1	21
5	Anthracycline-containing regimens for treatment of follicular lymphoma in adults. <i>The Cochrane Library</i> , 2013, , CD008909.	1.5	4
6	Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes. <i>Expert Review of Hematology</i> , 2013, 6, 525-537.	1.0	5
7	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. <i>Cancer</i> , 2013, 119, 4129-4136.	2.0	18
8	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet</i> , The, 2013, 382, 1094.	6.3	2
9	Bendamustine and Rituximab for Indolent B-Cell Non-Hodgkin Lymphoma in Patients With Compensated Hepatitis C Cirrhosis: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, e15-e17.	0.2	3
10	Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1403-1406.	2.0	25
11	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet</i> , The, 2013, 382, 1094-1095.	6.3	1
12	Treatment for patients with indolent and mantle cell lymphoma. <i>Lancet</i> , The, 2013, 382, 1093-1094.	6.3	0
13	First-line treatment of indolent lymphoma: axing CHOP?. <i>Lancet</i> , The, 2013, 381, 1163-1165.	6.3	10
14	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 1151-1179.	0.8	22
15	Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 703-711.	2.0	46
16	Current and Emerging Therapies in Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2013, 14, 198-211.	1.3	14
17	Mantle cell lymphoma: continuously improving the odds!. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 1001-1018.	0.5	0
18	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1937-1946.	1.2	35

#	ARTICLE	IF	CITATIONS
20	Dissecting follicular lymphoma: high versus low risk. Hematology American Society of Hematology Education Program, 2013, 2013, 561-567.	0.9	16
21	Transplantation for mantle cell lymphoma: is it the right thing to do?. Hematology American Society of Hematology Education Program, 2013, 2013, 568-574.	0.9	14
22	Rituximab for the treatment of follicular lymphoma. Future Oncology, 2013, 9, 1283-1298.	1.1	3
24	Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management. Oncologist, 2013, 18, 954-964.	1.9	26
25	Recent advances in the management of mantle cell lymphoma. Current Opinion in Oncology, 2013, 25, 716-721.	1.1	7
26	Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. Chemotherapy, 2013, 59, 280-289.	0.8	4
27	One Size Does Not Fit All in Follicular Lymphoma. Journal of Clinical Oncology, 2013, 31, 3307-3308.	0.8	6
28	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi155-vi159.	0.6	62
29	Toxic and drug-induced peripheral neuropathies. Current Opinion in Neurology, 2013, 26, 481-488.	1.8	22
30	David Versus Goliath: Decision Analysis Predicts Results of a Large Clinical Trial in Follicular Lymphoma. Journal of Clinical Oncology, 2013, 31, 3608-3609.	0.8	2
31	Indolent lymphoma—why not to sprint at the start of a marathon. Nature Reviews Clinical Oncology, 2013, 10, 251-252.	12.5	1
32	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood, 2013, 122, 1137-1143.	0.6	120
34	Management of mantle cell lymphoma in the elderly patient. Clinical Interventions in Aging, 2013, 8, 1229.	1.3	11
35	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	9
36	Follicular lymphoma. , 0, , 87-103.		0
37	What happened at EHA about mantle cell lymphoma?. Hematologie, 2014, 20, 142-152.	0.0	0
38	Mantle cell lymphoma: a model for risk-adapted treatment approach. Blood Research, 2014, 49, 1.	0.5	2
39	Treatment of Follicular Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2014, 54, 31-37.	0.3	19

#	ARTICLE	IF	CITATIONS
40	Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 191-198.	1.8	30
41	Current and future therapeutic approach for Waldenström's macroglobulinemia. Immunotherapy, 2014, 6, 333-348.	1.0	1
42	Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Pharmacotherapy, 2014, 15, 2443-2459.	0.9	32
43	Primary Gastrointestinal Mantle Cell Lymphoma: A Retrospective Study. Journal of Gastrointestinal Cancer, 2014, 45, 481-486.	0.6	10
45	Ibrutinib for the treatment of mantle cell lymphoma. Expert Review of Hematology, 2014, 7, 521-531.	1.0	10
46	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncology, 2014, 10, 957-967.	1.1	136
47	Management perspective for mantle cell lymphoma. International Journal of Hematologic Oncology, 2014, 3, 31-40.	0.7	0
49	Sixteenth Biannual Report of the Cochrane Haematological Malignancies Group: Focus on Non-Hodgkin's Lymphoma. Journal of the National Cancer Institute, 2014, 106, dju170-dju170.	3.0	5
50	Bendamustine: role and evidence in lymphoma therapy, an overview. Leukemia and Lymphoma, 2014, 55, 1471-1478.	0.6	19
52	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. BioMed Research International, 2014, 2014, 1-7.	0.9	4
53	Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Annals of Oncology, 2014, 25, 2020-2024.	0.6	29
54	A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events. Current Oncology, 2014, 21, 35-42.	0.9	4
55	Optimal disease surveillance strategies in non-Hodgkin lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 481-487.	0.9	12
56	Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs, 2014, 19, 367-383.	1.0	4
57	Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Annals of Oncology, 2014, 25, 1391-1397.	0.6	10
58	A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. British Journal of Haematology, 2014, 165, 768-776.	1.2	104
59	Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 11. autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. British Journal of Haematology, 2014, 166, 625-628.	1.2	3
60	First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematology, the, 2014, 1, e104-e111.	2.2	77

#	ARTICLE	IF	CITATIONS
61	Gastric MALT lymphoma – Update on diagnosis and treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1069-1077.	1.0	45
62	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood</i> , 2014, 123, 2944-2952.	0.6	505
64	Therapeutic approaches in patients with newly diagnosed follicular lymphoma. <i>Future Oncology</i> , 2014, 10, 1967-1980.	1.1	3
65	Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?. <i>Leukemia and Lymphoma</i> , 2014, 55, 1463-1470.	0.6	37
66	Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 1814-1822.	3.2	35
67	Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 95-107.	0.6	5
68	Role of ibrutinib for the treatment of mantle cell lymphoma in the elderly. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 53-61.	0.7	0
69	Bortezomib for the treatment of mantle cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1233-1241.	0.5	1
70	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii83-iii92.	0.6	129
71	Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2014, , 45.	1.2	0
72	Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 78-90.	1.1	6
73	Nodal marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1240-1250.	0.6	20
74	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014, 24, 33-42.	4.3	80
75	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014, 55, 988-998.	0.6	10
76	Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Annals of Hematology</i> , 2014, 93, 249-253.	0.8	39
77	Pleural decortication of a marginal zone lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1253-1254.	0.8	0
78	Ibrutinib in B-cell Lymphomas. <i>Current Treatment Options in Oncology</i> , 2014, 15, 226-237.	1.3	14
79	Follicular lymphoma: 2014 update on diagnosis and management. <i>American Journal of Hematology</i> , 2014, 89, 429-436.	2.0	54

#	ARTICLE	IF	CITATIONS
80	An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1119-1127.	1.1	8
81	How we manage follicular lymphoma. <i>Leukemia</i> , 2014, 28, 1388-1395.	3.3	83
82	Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma. <i>European Journal of Haematology</i> , 2014, 93, 469-475.	1.1	6
83	Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 708-709.	3.3	28
84	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. <i>Leukemia Research</i> , 2014, 38, 1446-1450.	0.4	13
85	Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2014, 165, 316-333.	1.2	52
86	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1311-1318.	5.1	239
87	Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymphoma in the Czech Republic. <i>Value in Health</i> , 2014, 17, A641.	0.1	0
88	Ibrutinib for the Treatment of Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5365-5371.	3.2	39
89	Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. <i>Journal of Medical Economics</i> , 2014, 17, 111-124.	1.0	13
92	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. <i>British Journal of Haematology</i> , 2014, 166, 514-520.	1.2	17
94	Current regimens and novel agents for mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 3-18.	1.2	16
95	How to manage mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 2117-2130.	3.3	44
96	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii76-iii82.	0.6	72
97	Pathogenesis, diagnosis, and treatment of composite lymphomas. <i>Lancet Oncology</i> , The, 2014, 15, e435-e446.	5.1	99
98	New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?. <i>Clinical Cancer Research</i> , 2014, 20, 5194-5206.	3.2	31
99	Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 945-970.	0.9	21
100	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1947-1956.	1.2	30

#	ARTICLE	IF	CITATIONS
101	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR [®] , _® therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. <i>Investigational New Drugs</i> , 2014, 32, 1213-1225.	1.2	21
102	Mantle Cell Lymphoma: Taking Therapeutic Advantage of New Insights into the Biology. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 254-261.	1.2	0
104	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. <i>Frontiers of Medicine</i> , 2014, 8, 254-258.	1.5	0
105	Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. <i>Medical Oncology</i> , 2014, 31, 944.	1.2	13
106	From empiric to mechanism-based therapy for peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 249-262.	0.7	16
107	Fractionated ⁹⁰ Y-ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. <i>Journal of Clinical Oncology</i> , 2014, 32, 212-218.	0.8	57
108	Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. <i>Annals of Hematology</i> , 2014, 93, 1551-1558.	0.8	12
109	Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 277-283.	0.2	21
110	Primary breast lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 900-908.	3.4	109
111	Non-Hodgkin's Lymphomas, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1282-1303.	2.3	144
112	Rituximab in follicular lymphoma: the first chapter of the new era?. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 267-273.	0.7	0
113	Overview on clinical trials in Waldenstrom's macroglobulinemia. <i>Clinical Investigation</i> , 2014, 4, 1139-1154.	0.0	0
115	Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. <i>Blood</i> , 2014, 124, 1288-1295.	0.6	113
116	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood</i> , 2014, 123, 1665-1673.	0.6	61
117	Indolent and mantle cell NHL: the future is BRIGHT. <i>Blood</i> , 2014, 123, 2905-2906.	0.6	2
118	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	0.6	138
119	How to treat old MCL patients: one size fits it all?. <i>Blood</i> , 2014, 124, 1207-1208.	0.6	7
120	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. <i>Blood</i> , 2014, 124, 2306-2312.	0.6	35

#	ARTICLE	IF	CITATIONS
121	Elevated soluble IL-2R^{\pm} , IL-8 , and MIP-1^2 levels are associated with inferior outcome and are independent of MIP-1 score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	2.0	36
122	Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome. <i>Case Reports in Oncology</i> , 2014, 7, 188-194.	0.3	2
123	Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab. <i>Case Reports in Oncology</i> , 2014, 7, 497-502.	0.3	3
124	Emerging Therapy for the Treatment of Mantle Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1311-1318.	2.3	5
125	Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. <i>Hematological Oncology</i> , 2014, 32, 192-196.	0.8	1
126	Waldenström macroglobulinemia at 70. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 253-266.	0.7	0
127	Mantle cell lymphoma: 2015 update on diagnosis, risk stratification, and clinical management. <i>American Journal of Hematology</i> , 2015, 90, 739-745.	2.0	83
128	Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	1.3	2
130	Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2015, 5, e362-e362.	2.8	46
131	Mantle cell lymphoma: evolving management strategies. <i>Blood</i> , 2015, 125, 48-55.	0.6	155
132	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 242-248.	0.6	124
133	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	0.6	161
134	Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. <i>Blood</i> , 2015, 126, 1407-1414.	0.6	28
135	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	0.6	108
136	Is Observation Dead in Follicular Lymphoma? No, But the Apoptosis Pathway Has Been Activated. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 363-366.	2.3	2
137	Chłoniak z komórek pączka "nawrot po leczeniu pierwszej linii. <i>Acta Haematologica Polonica</i> , 2015, 46, 112-117.	0.1	0
140	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 277-291.	0.6	3
141	SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 1014-1019.	1.2	8

#	ARTICLE	IF	CITATIONS
142	A phase III study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12
143	Combined systemic and ocular chemotherapy for anterior segment metastasis of systemic mantle cell lymphoma. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2015, 5, 30.	1.2	16
144	Follicular lymphoma: 2015 update on diagnosis and management. <i>American Journal of Hematology</i> , 2015, 90, 1171-1178.	2.0	28
145	A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease. <i>Pediatric Blood and Cancer</i> , 2015, 62, 905-908.	0.8	4
146	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 788-797.	1.2	11
147	Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2015, 22, 469-475.	1.2	0
148	Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. <i>British Journal of Haematology</i> , 2015, 169, 814-823.	1.2	5
149	Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. <i>Cancer</i> , 2015, 121, 2637-2645.	2.0	20
150	Management of the lymphomas and myeloma. , 0, , 450-472.		0
151	Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. <i>Cancer Management and Research</i> , 2015, 7, 319.	0.9	3
152	Mantle cells lymphoma: standards and news. <i>Hematologie</i> , 2015, 21, 169-176.	0.0	1
153	Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1663.	0.9	1
154	An Aggressive Transformation to EBV-Positive Hodgkin Lymphoma after Bendamustine-Containing Chemotherapy for Marginal Zone Lymphoma. <i>Journal of Hematology & Thromboembolic Diseases</i> , 2015, 4, .	0.1	0
155	An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. <i>Current Oncology</i> , 2015, 22, 260-271.	0.9	4
156	Skeletal Muscle Radio-Density Is an Independent Predictor of Response and Outcomes in Follicular Lymphoma Treated with Chemoimmunotherapy. <i>PLoS ONE</i> , 2015, 10, e0127589.	1.1	41
157	Bortezomib-Based Therapy for Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 2270-2271.	13.9	4
158	How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2015, 126, 721-732.	0.6	165
159	Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2015, 90, 346-354.	2.0	36

#	ARTICLE	IF	CITATIONS
161	Waldenström macroglobulinemia: What a hematologist needs to know. <i>Blood Reviews</i> , 2015, 29, 301-319.	2.8	37
162	Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 211-216.	1.1	1
163	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642.	0.6	55
164	Ofatumumab in the treatment of non-Hodgkin's lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1085-1091.	1.4	15
165	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.	2.0	3
166	Disseminated extranodal marginal zone lymphoma involving the gastrocnemius muscle with sural neurolymphomatosis. <i>Annals of Hematology</i> , 2015, 94, 1939-1940.	0.8	2
167	Outcomes of Treatment in Slovene Follicular Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 586-591.	0.2	1
168	Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3-anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. <i>Journal of Hematology and Oncology</i> , 2015, 8, 108.	6.9	30
169	Mantle cell lymphoma: Towards a personalized therapeutic strategy?. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT /Qverlock_10 Tf 50 4	0.1	0
171	Bortezomib in the treatment of mantle cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2807-2818.	1.1	11
172	B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity. <i>International Journal of Oncology</i> , 2015, 46, 2562-2572.	1.4	28
173	Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. <i>Annals of Hematology</i> , 2015, 94, 981-988.	0.8	21
174	Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia. <i>Cancer Treatment and Research</i> , 2015, 165, 177-195.	0.2	17
176	New therapies in non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 349-359.	1.1	5
177	Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2015, 94, 633-641.	0.8	29
178	Mantle cell lymphoma: observation to transplantation. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 37-48.	1.1	19
179	A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015, 26, 1667-1677.	0.6	80
180	Advances in the treatment of follicular lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 207-218.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. <i>Leukemia and Lymphoma</i> , 2015, 56, 559-567.	0.6	12
182	Survival Disparities by Insurance Type for Patients Aged 15-64 Years With Non-Hodgkin Lymphoma. <i>Oncologist</i> , 2015, 20, 554-561.	1.9	21
183	Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. <i>Leukemia</i> , 2015, 29, 1695-1701.	3.3	39
185	Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 242-252.	1.1	26
186	Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. <i>Oncologist</i> , 2015, 20, 915-925.	1.9	31
187	Follicular Lymphoma. <i>Turkish Journal of Haematology</i> , 2015, 32, 94-95.	0.2	0
188	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 791-808.	2.5	7
189	Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 2489-2490.	0.6	8
190	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
191	Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. <i>Leukemia</i> , 2015, 29, 668-676.	3.3	95
192	Follicular Lymphoma: First-Line Treatment Without Chemotherapy for Follicular Lymphoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 32.	1.3	7
193	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015, 21, 3853-3861.	3.2	20
194	Desenlaces clínicos en hematología: diez años de investigaciones en Pubmed. <i>Revista Colombiana De Cancerología</i> , 2015, 19, 95-102.	0.0	3
195	A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. <i>British Journal of Haematology</i> , 2015, 169, 528-533.	1.2	12
197	Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1143-1154.	1.1	32
198	Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1689-1695.	1.2	16
199	Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. <i>International Journal of Hematology</i> , 2015, 102, 53-58.	0.7	6
201	Mucosa-associated lymphoid tissue lymphoma: a perspective on current and future therapeutic strategies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 577-586.	0.5	0

#	ARTICLE	IF	CITATIONS
202	Current Therapeutic Strategies and New Treatment Paradigms for Follicular Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 197-226.	0.2	9
203	Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. <i>Current Treatment Options in Oncology</i> , 2015, 16, 29.	1.3	2
204	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.1	0
205	Treatment Strategies in Mantle Cell Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 251-270.	0.2	9
206	Lymphoma in older patients: clinical and therapeutic characteristics. <i>Reviews in Clinical Gerontology</i> , 2015, 25, 1-11.	0.5	0
207	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. <i>Future Oncology</i> , 2015, 11, 1327-1342.	1.1	61
208	Bendamustine and the immune system: a wolf in sheep's clothing?. <i>Leukemia and Lymphoma</i> , 2015, 56, 837-838.	0.6	2
209	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 944-953.	13.9	343
210	Mantle cell lymphoma complicated by multiple widespread extranodal gastrointestinal lesions. <i>Endoscopy</i> , 2015, 47, E91-E93.	1.0	0
211	Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice. <i>Annals of Hematology</i> , 2015, 94, 1553-1558.	0.8	10
212	Novel Agents in Mantle Cell Lymphoma. <i>Current Oncology Reports</i> , 2015, 17, 34.	1.8	5
213	Indolent lymphoma at ASH 2014: new kids on the block (iDrugs). <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 166-169.	0.3	1
214	Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 1835-1844.	13.9	201
215	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> . 2015, 56, 2365-2372.	0.6	2
216	Comparative effectiveness of treatments for newly diagnosed follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2728-2730.	0.6	0
217	B Cell Lymphoma with Lung Involvement: What Is It about?. <i>Acta Haematologica</i> , 2015, 133, 221-225.	0.7	11
218	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1143-1156.	1.1	5
219	Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1123-1125.	0.6	20

#	ARTICLE	IF	CITATIONS
220	Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 942-950.	0.6	14
221	Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. <i>Annals of Hematology</i> , 2015, 94, 2025-2032.	0.8	26
222	Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1337-1349.	1.1	5
223	Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. <i>Medical Oncology</i> , 2015, 32, 232.	1.2	0
224	Waldenstrom macroglobulinemia: prognosis and management. <i>Blood Cancer Journal</i> , 2015, 5, e394-e394.	2.8	41
225	Phase II clinical trials for Waldenstrom's macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 537-547.	0.5	0
226	Mantle Cell Lymphoma. , 2015, , 233-243.		1
227	Non-Hodgkin Lymphoma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1152-1163.	1.4	115
228	Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes. <i>Expert Review of Hematology</i> , 2015, 8, 581-593.	1.0	19
229	Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S141-S146.	0.2	1
230	Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab. <i>Annals of Hematology</i> , 2015, 94, 2061-2062.	0.8	2
231	Treatment options for mantle cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2497-2507.	0.9	9
232	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. <i>Leukemia and Lymphoma</i> , 2015, 56, 1295-1302.	0.6	22
233	Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. <i>British Journal of Haematology</i> , 2015, 168, 317-327.	1.2	225
234	Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs. <i>Pharmacological Research</i> , 2015, 91, 78-87.	3.1	28
235	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 59-74.	0.2	17
236	Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. <i>Blood Reviews</i> , 2015, 29, 143-152.	2.8	8
237	Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>Hematological Oncology</i> , 2015, 33, 136-144.	0.8	2

#	ARTICLE	IF	CITATIONS
238	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 75-85.	0.2	32
239	Phase II study of first-line ¹³¹ I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic ¹⁸ F-fluorodeoxyglucose positron emission tomography. <i>Leukemia and Lymphoma</i> , 2015, 56, 1271-1277.	0.6	22
240	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). <i>Leukemia and Lymphoma</i> , 2015, 56, 958-964.	0.6	36
241	Low-dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 277-278.	1.1	0
242	Role of allogeneic stem cell transplantation in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 290-297.	1.1	11
243	Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2016, 1, 122-131.	2.5	15
244	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, 6, 1.	1.2	8
245	Waldenström's macroglobulinemia: biology, genetics, and therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, Volume 6, 49-58.	1.2	6
246	SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016062.	0.5	4
247	Herpetic esophagitis following bendamustine-containing regimen. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 883.	0.9	1
248	FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017009.	0.5	13
249	THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016045.	0.5	4
250	Intérêt de l'obinutuzumab (GA101) associée à la chimiothérapie dans le lymphome non hodgkinien indolent réfractaire au rituximab: résultats de l'étude de phase III Gadalim. <i>Hematologie</i> , 2016, 22, 311-313.	0.0	0
251	Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma. <i>Current Oncology</i> , 2016, 23, 407-417.	0.9	8
252	BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016030.	0.5	6
253	Sjögren's Syndrome "Associated Lymphoma. , 2016, , 73-98.		0
254	Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation. <i>Case Reports in Hematology</i> , 2016, 2016, 1-3.	0.3	1
255	Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. <i>OncoTargets and Therapy</i> , 2016, 9, 2945.	1.0	24

#	ARTICLE	IF	CITATIONS
256	A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT) Tj ETQqO 0 0 rgBT /Overlock 10 T Oncology, 2016, 34, 177-183.	0.8	48
257	Phase II trial of CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601 . British Journal of Haematology, 2016, 172, 208-218.	1.2	45
258	Current and emerging treatment approaches for splenic marginal zone lymphoma. Expert Opinion on Orphan Drugs, 2016, 4, 897-905.	0.5	1
259	Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2016, 68, 977-985.	2.9	146
260	Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematological Oncology, 2016, 34, 200-207.	0.8	5
261	Mantle cell lymphoma treatment: plus 5a change. Lancet, The, 2016, 388, 535-536.	6.3	3
262	Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. European Journal of Haematology, 2016, 96, 532-540.	1.1	2
263	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood, 2016, 128, 1814-1820.	0.6	75
264	Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer, 2016, 16, 598.	1.1	6
265	Treatment of the elderly patient with mantle cell lymphoma. Hematology American Society of Hematology Education Program, 2016, 2016, 425-431.	0.9	6
266	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood, 2016, 128, 2510-2516.	0.6	56
267	Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?. Hematology American Society of Hematology Education Program, 2016, 2016, 277-283.	0.9	7
268	Frontline therapy and role of high-dose consolidation in mantle cell lymphoma. Hematology American Society of Hematology Education Program, 2016, 2016, 419-424.	0.9	4
269	Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematology American Society of Hematology Education Program, 2016, 2016, 437-445.	0.9	37
271	Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. Annals of Hematology, 2016, 95, 1259-1269.	0.8	11
272	Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thrombosis Research, 2016, 143, 86-90.	0.8	37
273	Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic Advances in Hematology, 2016, 7, 196-208.	1.1	39
275	Obinutuzumab for the treatment of indolent lymphoma. Future Oncology, 2016, 12, 1769-1781.	1.1	8

#	ARTICLE	IF	CITATIONS
276	Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. Current Hematologic Malignancy Reports, 2016, 11, 218-223.	1.2	0
277	Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Current Hematologic Malignancy Reports, 2016, 11, 234-240.	1.2	8
278	Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied Health Economics and Health Policy, 2016, 14, 465-477.	1.0	7
279	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. Annals of Hematology, 2016, 95, 1107-1114.	0.8	25
280	Mantle Cell Lymphoma (MCL). , 2016, , 183-195.		0
281	PET/CT in Lymphomas. , 2016, , .		4
282	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biology of Blood and Marrow Transplantation, 2016, 22, 1543-1551.	2.0	42
283	Follicular lymphoma: evolving therapeutic strategies. Blood, 2016, 127, 2055-2063.	0.6	142
284	Splenic marginal zone lymphoma: from genetics to management. Blood, 2016, 127, 2072-2081.	0.6	142
285	Optimizing therapy for nodal marginal zone lymphoma. Blood, 2016, 127, 2064-2071.	0.6	59
286	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 2016, 128, 1321-1328.	0.6	161
287	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood, 2016, 128, 1112-1120.	0.6	177
288	The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Expert Opinion on Drug Discovery, 2016, 11, 1123-1130.	2.5	5
289	Speed bumps on the road to a chemotherapy-free world for lymphoma patients. Blood, 2016, 128, 325-330.	0.6	17
290	Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 194-205.	0.7	5
291	Mantle cell lymphoma, response to treatment and prognosis in 45 patients. Medicina Clínica (English) Tj ETQq1 1 0.784314 ggBT /Over	0.1	0
292	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. Haematologica, 2016, 101, e411-e414.	1.7	11
293	Plasma Cell Dyscrasias. Cancer Treatment and Research, 2016, , .	0.2	3

#	ARTICLE	IF	CITATIONS
294	Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. <i>Cancer Treatment and Research</i> , 2016, 169, 321-361.	0.2	6
295	Primary gynecological non-Hodgkin's lymphoma: A differential diagnosis of a pelvic mass. <i>Gynecologic Oncology Reports</i> , 2016, 18, 29-31.	0.3	12
296	Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 5-17.	2.0	78
297	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. <i>Oncologist</i> , 2016, 21, 1377-1386.	1.9	36
298	Rituximab intolerance in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 174, 645-648.	1.2	34
299	Premature closure of a phase III study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. <i>British Journal of Haematology</i> , 2016, 175, 531-533.	1.2	7
300	Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 152-171.	157.7	177
301	New drugs for follicular lymphoma. <i>Leukemia Research</i> , 2016, 49, 38-46.	0.4	3
302	Reappraising the timing of transplant for indolent non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2016, 9, 951-964.	1.0	1
303	Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma. <i>Cancer Investigation</i> , 2016, 34, 279-285.	0.6	6
304	Lymphoma. <i>Primary Care - Clinics in Office Practice</i> , 2016, 43, 661-675.	0.7	93
305	Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1345-1370.	0.9	5
306	Handbook of Lymphoma. , 2016, , .		3
307	A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 281-289.	1.2	50
308	Treatment of primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2016, 12, 456-471.	3.5	137
309	Lenalidomide for the treatment of B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1103-1116.	1.9	20
310	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 179-186.	1.1	28
311	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v83-v90.	0.6	166

#	ARTICLE	IF	CITATIONS
312	Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. <i>Acta Haematologica</i> , 2016, 136, 244-255.	0.7	10
313	Combined therapy in MCL: less may be more?. <i>Blood</i> , 2016, 128, 1782-1783.	0.6	1
314	Plasma Cell Disorders. Primary Care - Clinics in Office Practice, 2016, 43, 677-691.	0.7	22
315	Sjögren syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16047.	18.1	511
316	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	2.0	22
317	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
318	Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 118-126.	2.0	21
319	Bullae And Blisters: A Rare Case of Bendamustine Skin Toxicity. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 368-369.	0.3	6
320	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrzaji plazmocytowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.1	10
321	A phase 2 study of Rituximab+ Bendamustine and Rituximab+ Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	1.2	51
322	Efficacy of the GemOx+R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 899-910.	1.2	13
323	Temsirolimus acts as additive with bendamustine in aggressive lymphoma. <i>Annals of Hematology</i> , 2016, 95, 403-407.	0.8	9
324	Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 483-492.	1.0	13
325	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 182-190.e1.	0.2	15
326	Bendamustine associated immune suppression and infections during therapy of hematological malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 512-519.	0.6	57
327	Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 57-66.	1.4	11
328	Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 57-66.	5.1	133
329	Mature answers but new questions in indolent and mantle-cell lymphoma. <i>Lancet Oncology</i> , The, 2016, 17, 6-8.	5.1	5

#	ARTICLE	IF	CITATIONS
330	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. <i>Current Treatment Options in Oncology</i> , 2016, 17, 16.	1.3	12
331	Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. <i>Leukemia Research</i> , 2016, 44, 53-60.	0.4	25
332	p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study. <i>Molecular Oncology</i> , 2016, 10, 148-156.	2.1	9
334	Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. <i>Oncology Letters</i> , 2016, 11, 654-656.	0.8	3
335	90Y-ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 82-88.	0.2	6
336	Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. <i>Annals of Oncology</i> , 2016, 27, 895-901.	0.6	20
338	Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. <i>Leukemia and Lymphoma</i> , 2016, 57, 1149-1153.	0.6	6
339	Novel targeted therapeutics for mantle cell lymphoma – What’s on the horizon?. <i>Expert Review of Hematology</i> , 2016, 9, 271-281.	1.0	2
340	Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1256-1269.	0.8	247
341	Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. <i>Bone Marrow Transplantation</i> , 2016, 51, 319-321.	1.3	32
342	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	0.6	30
343	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 175-189.	1.0	7
344	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. <i>Leukemia and Lymphoma</i> , 2016, 57, 766-782.	0.6	70
345	Bendamustine reactivates latent Epstein-Barr virus. <i>Leukemia and Lymphoma</i> , 2016, 57, 1208-1210.	0.6	5
346	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 880-887.	0.6	9
347	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016, 57, 63-69.	0.6	25
348	Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. <i>Leukemia and Lymphoma</i> , 2016, 57, 692-699.	0.6	10
349	L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 61-68.	0.3	1

#	ARTICLE	IF	CITATIONS
350	Treatment approaches of hard-to-treat non-Hodgkin lymphomas. Expert Review of Hematology, 2017, 10, 259-273.	1.0	9
351	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. Annals of Hematology, 2017, 96, 639-646.	0.8	7
352	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2017, 47, 35-49.	0.5	10
353	Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw255.	3.0	23
354	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Advances in Therapy, 2017, 34, 324-356.	1.3	128
355	Pólipo cónico como forma de presentación de linfoma del manto. Gastroenterología y Hepatología, 2017, 40, 682-684.	0.2	0
356	Non-Hodgkin lymphoma. Lancet, The, 2017, 390, 298-310.	6.3	615
357	Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2017, 92, 209-217.	2.0	42
358	Another bidder (BDR) revisits. Blood, 2017, 129, 398-400.	0.6	8
359	Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies. AAPS Journal, 2017, 19, 669-681.	2.2	8
360	A concise review of lenalidomide therapy for follicular lymphoma. Expert Opinion on Orphan Drugs, 2017, 1-7.	0.5	0
361	Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961769130.	0.3	0
362	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood, 2017, 129, 2224-2232.	0.6	243
363	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. Hematological Oncology, 2017, 35, 520-527.	0.8	20
364	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica, 2017, 102, 765-772.	1.7	21
365	Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, 2017, 102, 895-902.	1.7	6
366	Case 11-2017 " A 61-Year-Old Woman with Leg Swelling, Back Pain, and Hydronephrosis. New England Journal of Medicine, 2017, 376, 1461-1471.	13.9	1
367	Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 99-115.	0.6	14

#	ARTICLE	IF	CITATIONS
368	Efficacy in the margins of NHL with ibrutinib. <i>Blood</i> , 2017, 129, 2207-2208.	0.6	0
369	Unmet needs in the first-line treatment of follicular lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2094-2106.	0.6	31
370	Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1264-1268.	2.0	1
371	Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20%. <i>Chemotherapy</i> , 2017, 62, 140-146.	0.8	0
372	Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. <i>Oncologist</i> , 2017, 22, 549-553.	1.9	4
373	Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus. <i>Annals of Hematology</i> , 2017, 96, 1221-1222.	0.8	6
374	Management of macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 177, 669-671.	1.2	1
375	Role of plasma cells in Waldenström macroglobulinaemia. <i>Pathology</i> , 2017, 49, 337-345.	0.3	14
376	Management of Lymphomas: A Case-Based Approach. , 2017, , .		0
377	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
378	Mantle cell lymphoma – Current standards of care and future directions. <i>Cancer Treatment Reviews</i> , 2017, 58, 51-60.	3.4	12
379	Chemotherapy free treatment of indolent lymphoma. <i>Hematological Oncology</i> , 2017, 35, 20-24.	0.8	1
380	Current options to manage Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2017, 10, 637-647.	1.0	4
381	Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. <i>Blood</i> , 2017, 130, 537-541.	0.6	98
382	Targeting non-Hodgkin lymphoma with blinatumomab. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1013-1017.	1.4	12
383	Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1631-1640.	2.0	32
384	Rituximab maintenance improves overall survival of patients with follicular lymphoma – Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 76, 216-225.	1.3	50
385	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017, 177, 263-270.	1.2	14

#	ARTICLE	IF	CITATIONS
386	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 252-262.	0.2	38
387	Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. <i>International Journal of Hematology</i> , 2017, 105, 658-667.	0.7	4
388	Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). <i>Annals of Oncology</i> , 2017, 28, 836-842.	0.6	87
389	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. <i>Leukemia and Lymphoma</i> , 2017, 58, 1805-1813.	0.6	13
390	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw263.	3.0	10
391	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
392	Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. <i>International Journal of Hematology</i> , 2017, 105, 470-477.	0.7	12
393	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	1.2	40
395	Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?. <i>New England Journal of Medicine</i> , 2017, 377, 1389-1390.	13.9	8
396	Current challenges in the management of follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 13-24.	0.7	1
397	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	1.3	407
398	Autologous hematopoietic cell transplantation of mantle cell lymphoma. <i>Current Opinion in Hematology</i> , 2017, 24, 502-508.	1.2	3
399	Orbital mantle cell lymphoma presenting as myasthenia gravis. <i>Orbit</i> , 2017, 36, 365-369.	0.5	10
400	Radiation Therapy in Mantle Cell Lymphoma. , 2017, , 1-14.		0
401	Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 106-115.	1.2	14
402	Zalecenia Polskiej Grupy Szpiczakowej dotyczą...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytoowych na rok 2017. <i>Acta Haematologica Polonica</i> , 2017, 48, 55-103.	0.1	5
403	Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 797-803.	0.2	15
404	Mantle cell lymphoma: 2017 update on diagnosis, risk stratification, and clinical management. <i>American Journal of Hematology</i> , 2017, 92, 806-813.	2.0	149

#	ARTICLE	IF	CITATIONS
405	Current and emerging treatment options for mantle cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 223-234.	1.1	20
406	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
407	Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. <i>Journal of Drug Assessment</i> , 2017, 6, 10-17.	1.1	20
408	Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1393308.	0.8	1
411	Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the Stil NHL1 trial. <i>Annals of Hematology</i> , 2017, 96, 1155-1162.	0.8	6
412	Retrospective analysis of prognostic factors for Waldenström macroglobulinemia: a multicenter cooperative study in Japan. <i>International Journal of Hematology</i> , 2017, 106, 681-690.	0.7	3
413	Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 637-644.	0.2	14
414	Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 909-915.	1.9	30
415	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017, 10, 707-718.	1.0	8
416	Treatment of splenic marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 139-148.	0.7	23
417	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597.	0.6	2
418	Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 92-98.	0.7	13
419	Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. <i>Leukemia</i> , 2017, 31, 517-519.	3.3	14
420	Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. <i>Supportive Care in Cancer</i> , 2017, 25, 839-845.	1.0	20
421	Marginal zone lymphoma in elderly and geriatric patients. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 158-165.	0.7	8
422	The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 536-541.	0.8	13
423	¹⁸ F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine+Rituximab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 62-68.	2.8	15
424	Bendamustine-associated infections – systematic review and meta-analysis of randomized controlled trials. <i>Hematological Oncology</i> , 2017, 35, 424-431.	0.8	21

#	ARTICLE	IF	CITATIONS
425	Follicular dendritic cell sarcoma treated with a variety of chemotherapy. <i>Hematological Oncology</i> , 2017, 35, 905-908.	0.8	15
427	Immunotherapy in Waldenstrom's Macroglobulinemia. , 2017, , 315-326.		0
428	Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia. , 2017, , 357-365.		1
429	Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. <i>Leukemia and Lymphoma</i> , 2017, 58, 601-613.	0.6	7
430	Biology and Management of Unusual Plasma Cell Dyscrasias. , 2017, , .		0
431	Waldenstrom's Macroglobulinemia. , 2017, , 71-93.		0
432	Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. <i>Bone Marrow Transplantation</i> , 2017, 52, 28-33.	1.3	11
433	High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. <i>Blood Cancer Journal</i> , 2017, 7, e614-e614.	2.8	11
434	Single colonic polyp as a presentation of mantle cell lymphoma. <i>Gastroenterology & Hepatology (English Edition)</i> , 2017, 40, 682-684.	0.0	0
435	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv62-iv71.	0.6	387
437	Hematopoietic cell transplants for Hodgkin lymphoma. , 0, , 361-371.		0
438	Hematopoietic cell transplants for indolent lymphomas. , 0, , 392-401.		0
439	Hematopoietic cell transplants for mantle cell lymphoma. , 0, , 402-416.		0
441	An Update on Tumors of the Lacrimal Gland. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 159-172.	1.3	53
442	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 371-378.	0.9	24
443	Toward personalized treatment in Waldenström macroglobulinemia. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 365-370.	0.9	7
444	The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 413.	1.6	4
445	The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2038.	1.8	1

#	ARTICLE	IF	CITATIONS
446	Updates from the 2016 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Follicular Lymphoma. <i>Current Oncology</i> , 2017, 24, 52-60.	0.9	0
447	Impact of obinutuzumab alone and in combination for follicular lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017, Volume 7, 73-83.	1.2	1
448	New developments in the management of Waldenström's macroglobulinemia. <i>Cancer Management and Research</i> , 2017, Volume 9, 73-83.	0.9	13
449	Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape. <i>Cancer Management and Research</i> , 2017, Volume 9, 131-140.	0.9	18
450	ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma. <i>Current Oncology</i> , 2017, 24, 262-370.	0.9	0
451	The clinical development of obinutuzumab for the treatment of follicular lymphoma. <i>Cancer Management and Research</i> , 2017, Volume 9, 103-113.	0.9	4
452	Efficacy of bendamustine on thrombocytopenia and hemolytic anemia secondary to CD5-positive B-cell lymphoma with massive splenomegaly in a patient with rheumatoid arthritis. <i>Molecular and Clinical Oncology</i> , 2017, 7, 855-858.	0.4	2
453	Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenström's macroglobulinemia and review of the literature. <i>Dermatology Reports</i> , 2017, 9, 6976.	0.4	16
454	Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick. <i>Journal of Clinical Oncology</i> , 2017, 35, 1872-1878.	0.8	3
455	Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?. <i>Journal of Oncology Practice</i> , 2017, 13, e139-e151.	2.5	1
456	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 512-525.	1.8	16
457	Risk stratification in follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 15-22.	0.7	12
458	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström's macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 181, 77-85.	1.2	41
459	Does maintenance therapy have a role in mantle cell lymphoma treatment?. <i>Expert Review of Hematology</i> , 2018, 11, 285-292.	1.0	1
460	Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. <i>American Journal of Hematology</i> , 2018, 93, 356-362.	2.0	6
461	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. <i>Haematologica</i> , 2018, 103, e151-e153.	1.7	22
462	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
463	Have we found the right patient population for transplantation in follicular lymphoma?. <i>Cancer</i> , 2018, 124, 2484-2487.	2.0	0

#	ARTICLE	IF	CITATIONS
464	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2018, 24, 3247-3252.	3.2	57
465	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
466	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
467	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 28-37.	1.1	8
468	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	0.8	16
469	Pathology of Non-Hodgkin and Hodgkin Lymphomas. , 2018, , 773-826.		0
470	How we manage patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 181, 737-751.	1.2	8
471	CAR T cell therapy for B-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 135-146.	0.7	39
472	Waldenström's Macroglobulinemia. <i>Hematologic Malignancies</i> , 2018, , 191-220.	0.2	2
474	Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. <i>Bone Marrow Transplantation</i> , 2018, 53, 780-783.	1.3	6
475	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2018, 4, 744.	3.4	0
476	Current status and progress of lymphoma management in China. <i>International Journal of Hematology</i> , 2018, 107, 405-412.	0.7	26
477	Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review. <i>Annals of Hematology</i> , 2018, 97, 821-829.	0.8	7
478	Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma. <i>Experimental Hematology</i> , 2018, 59, 72-81.e2.	0.2	9
479	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	0.6	5
480	Treatment of mantle cell lymphoma in older adults. <i>Journal of Geriatric Oncology</i> , 2018, 9, 308-314.	0.5	4
481	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. <i>Annals of Oncology</i> , 2018, 29, 332-340.	0.6	20
482	Follicular lymphoma: 2018 update on diagnosis and management. <i>American Journal of Hematology</i> , 2018, 93, 296-305.	2.0	87

#	ARTICLE	IF	CITATIONS
483	Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics. <i>International Journal of Clinical Oncology</i> , 2018, 23, 375-381.	1.0	1
485	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
486	Waldenström macroglobulinemia treatment algorithm 2018. <i>Blood Cancer Journal</i> , 2018, 8, 40.	2.8	17
487	Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with ⁹⁰ Y ibritumomab tiuxetan in a phase II study. <i>Hematological Oncology</i> , 2018, 36, 525-532.	0.8	4
488	Indolent lymphoma at ASH (American Society of Hematology) 2017: maintenance revisited. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 101-104.	0.3	0
489	Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and review of the literature. <i>Journal of Oncological Science</i> , 2018, 4, 56-59.	0.1	2
490	Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 82-84.	0.9	0
491	Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN). <i>British Journal of Haematology</i> , 2018, 181, 215-228.	1.2	36
492	Long-Term Outcomes of 107 Cases of Primary Thyroid Mucosa-Associated Lymphoid Tissue Lymphoma at a Single Medical Institution in Japan. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 732-739.	1.8	26
493	Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. <i>Current Oncology Reports</i> , 2018, 20, 33.	1.8	20
494	Impact of age on genetics and treatment efficacy in follicular lymphoma. <i>Haematologica</i> , 2018, 103, e364-e367.	1.7	10
495	The degree of overlap between the follicular dendritic cell meshwork and tumor cells in mantle cell lymphoma is associated with prognosis. <i>Pathology Research and Practice</i> , 2018, 214, 513-520.	1.0	3
496	Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 555-559.	1.2	13
497	Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 297-301.	1.2	7
498	What is the optimal initial management of the older MCL patient?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 99-104.	0.7	8
499	A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Hematological Oncology</i> , 2018, 36, 49-55.	0.8	12
500	Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab. <i>Hematological Oncology</i> , 2018, 36, 144-149.	0.8	6
501	Current prognostic and predictive factors in follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 209-227.	0.8	22

#	ARTICLE	IF	CITATIONS
502	Transformed follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 17-29.	0.8	58
503	Alternating R-CHOP and R-ycytarabine is a safe and effective regimen for transplant-eligible patients with a newly diagnosed mantle cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 110-115.	0.8	18
504	Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14). <i>Leukemia and Lymphoma</i> , 2018, 59, 1606-1613.	0.6	1
505	The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 52-59.	1.2	8
506	Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. <i>American Journal of Hematology</i> , 2018, 93, E1-E3.	2.0	15
507	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 58-64.	0.2	10
508	Chimeric antigen receptor T-cell therapies for lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 31-46.	12.5	391
509	Management of untreated advanced stage follicular lymphoma: Role of patient discernment. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 23-30.	0.7	1
510	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018, 59, 1814-1828.	0.6	23
511	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
512	Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 365-373.	1.2	10
513	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e95-e102.	0.2	6
514	Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 65-72.	0.7	11
515	Novel therapies for relapsed/refractory mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 105-113.	0.7	10
516	Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2749-2751.	0.8	2
517	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
518	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹ I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	0.8	68
519	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. <i>Journal of Clinical Oncology</i> , 2018, 36, 2395-2404.	0.8	165

#	ARTICLE	IF	CITATIONS
520	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2755-2761.	0.8	142
521	Identification of TRAF6-positive cells as a potent refractory population in follicular lymphomas. <i>Cancer Science</i> , 2018, 110, 443-457.	1.7	7
522	Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia. <i>Acta Clinica Croatica</i> , 2018, 57, 542-553.	0.1	10
523	Rituximab Maintenance Therapy and Bendamustine Containing Treatments may improve the Survival of Mantle Cell Lymphoma: Retrospective Analysis in Single Institute. <i>Journal of Blood & Lymph</i> , 2018, 08, .	0.0	0
524	New Treatment Options in Advanced Stage Follicular Lymphoma. <i>HemaSphere</i> , 2018, 2, e156.	1.2	1
525	Chemotherapy-free induction in MCL: ready for prime time?. <i>Blood</i> , 2018, 132, 2001-2002.	0.6	1
526	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	1.2	41
527	Ibrutinib and Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 379, 1973-1976.	13.9	7
528	Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. <i>Current Treatment Options in Oncology</i> , 2018, 19, 71.	1.3	6
529	Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. <i>Lancet Haematology</i> , 2018, 5, e520-e531.	2.2	14
530	Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. <i>British Journal of Haematology</i> , 2019, 184, 957-968.	1.2	39
531	WALDENSTROM'S MACROGLOBULINEMIA: AN UPDATE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018004.	0.5	21
532	Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. <i>Blood Research</i> , 2018, 53, 117.	0.5	4
533	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv41-iv50.	0.6	63
534	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2018, 19, 1449-1458.	5.1	93
535	Bortezomib-based chemotherapy in mantle cell lymphoma. <i>Lancet Oncology</i> , 2018, 19, 1419-1421.	5.1	6
536	Frontline Treatment for Older Patients with Mantle Cell Lymphoma. <i>Oncologist</i> , 2018, 23, 1337-1348.	1.9	10
537	Optimal frontline management of mantle cell lymphoma: can we agree?. <i>Expert Review of Hematology</i> , 2018, 11, 911-914.	1.0	1

#	ARTICLE	IF	CITATIONS
538	Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. <i>Blood</i> , 2018, 132, 2016-2025.	0.6	93
539	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018, 183, 601-607.	1.2	7
540	Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27415.	0.8	2
541	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	13.9	264
542	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	2.2	21
543	Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study. <i>British Journal of Haematology</i> , 2018, 183, 564-577.	1.2	12
544	Current overview and treatment of mantle cell lymphoma. <i>F1000Research</i> , 2018, 7, 1136.	0.8	32
545	Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4817-4827.	1.0	40
546	Do We Need Maintenance with Anti-CD20 Antibody after First-Line Therapy for All Newly Diagnosed Follicular Lymphoma Patients?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S104-S105.	0.2	0
547	The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 829-835.	0.2	2
548	Where to start? Upfront therapy for follicular lymphoma in 2018. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 185-188.	0.9	7
549	Sequencing of therapies in relapsed follicular lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 189-193.	0.9	9
550	Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. <i>Blood Advances</i> , 2018, 2, 1562-1571.	2.5	10
551	High-dose Bendamustine (EAM) followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. <i>European Journal of Haematology</i> , 2018, 101, 326-331.	1.1	13
552	Follicular Lymphoma: Past, Present, and Future. <i>Current Treatment Options in Oncology</i> , 2018, 19, 32.	1.3	10
553	Guideline for the management of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 46-62.	1.2	38
554	A safety profile of medications used to treat Waldenström's macroglobulinemia. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 609-621.	1.0	2
555	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 111-122.	1.0	14

#	ARTICLE	IF	CITATIONS
556	Non-Hodgkin's Lymphoma. , 2018, , 757-768.		0
557	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. New England Journal of Medicine, 2018, 378, 2399-2410.	13.9	291
558	Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Medicine, 2018, 7, 2903-2912.	1.3	6
559	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematology,the, 2018, 5, e299-e309.	2.2	41
560	The real world of Waldenström's macroglobulinaemia. Lancet Haematology,the, 2018, 5, e275-e276.	2.2	2
561	Identification on Mantle Cell Lymphoma Using CD20 and CD5 Coupled Upconversion Fluorescent Nanoprobes. Journal of Nanomaterials, 2018, 2018, 1-12.	1.5	0
562	Chemical Therapy. , 2018, , 263-281.		0
563	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2018, , 951-973.		0
564	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Management and Research, 2018, Volume 10, 615-624.	0.9	24
565	Monoclonal Antibodies for Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 841-852.	0.9	0
566	Alkylating Agents in the Treatment of Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 821-827.	0.9	3
567	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	3.3	81
568	Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma. OncoTargets and Therapy, 2018, Volume 11, 3869-3882.	1.0	5
569	Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma. , 2018, , 1288-1297.e3.		0
570	Mantle Cell Lymphoma. , 2018, , 1298-1308.e2.		1
571	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
572	Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. Frontiers in Medicine, 2018, 5, 102.	1.2	64
573	Cancer Immunotherapy and the Immune Response in Follicular Lymphoma. Frontiers in Oncology, 2018, 8, 219.	1.3	11

#	ARTICLE	IF	CITATIONS
574	Current and future therapeutic approaches for the treatment of follicular lymphoma. Expert Review of Anticancer Therapy, 2018, 18, 931-941.	1.1	0
575	Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. Best Practice and Research in Clinical Haematology, 2018, 31, 285-292.	0.7	6
576	Waldenstromâ€™s Macroglobulinemia. , 2018, , 617-638.		0
577	Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide realâ€world analysis from Taiwan Cancer Registry Database. Cancer Medicine, 2018, 7, 3582-3591.	1.3	7
578	Evolving treatment strategies in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2018, 31, 270-278.	0.7	6
579	Current trials for frontline therapy of mantle cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 13.	6.9	12
580	Bendamustine and rituximab in elderly patients with lowâ€tumour burden follicular lymphoma. Results of the <sc>LYSA</sc> phase <sc>II BRIEF</sc> study. British Journal of Haematology, 2018, 183, 76-86.	1.2	14
581	Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines and Immunotherapeutics, 2018, 14, 2820-2841.	1.4	68
582	Potential loss of prognostic significance of minimal residual disease assessment after Râ€CHOPâ€based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematological Oncology, 2018, 36, 773-778.	0.8	10
583	Renewed interest for lowâ€dose radiation therapy in follicular lymphomas: From biology to clinical applications. Hematological Oncology, 2018, 36, 723-732.	0.8	3
584	Update on mantle cell lymphoma. Blood, 2018, 132, 1647-1656.	0.6	144
585	Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 398-421.	0.3	9
586	Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. Journal of Clinical Oncology, 2018, 36, 2918-2925.	0.8	76
587	Non-Hodgkin lymphoma. BMJ: British Medical Journal, 2018, 362, k3204.	2.4	60
588	Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood, 2018, 132, 761-764.	0.6	25
589	Gastric Cardiac Cancer. , 2018, , .		2
590	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leukemia and Lymphoma, 2018, 59, 2769-2781.	0.6	14
592	Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clinical Infectious Diseases, 2019, 68, 247-255.	2.9	42

#	ARTICLE	IF	CITATIONS
593	Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. <i>Leukemia and Lymphoma</i> , 2019, 60, 133-141.	0.6	16
594	Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia. <i>Future Oncology</i> , 2019, 15, 2687-2697.	1.1	0
595	Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. <i>F1000Research</i> , 2019, 8, 294.	0.8	4
596	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-2. Marginal zone lymphoma (MALT lymphoma/extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue and) <i>TJ ETQq1 1 0.784314 rgB74/Overlook</i>	1.1	14
597	Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. <i>Reviews in Medical Virology</i> , 2019, 29, e2077.	3.9	74
599	Clinical management of mantle cell lymphoma in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1893-1905.	0.9	3
600	Frontline therapies for untreated chronic lymphoid leukemia. <i>Experimental Hematology and Oncology</i> , 2019, 8, 15.	2.0	11
601	The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 528.	1.3	27
602	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. <i>Blood</i> , 2019, 134, 761-764.	0.6	77
603	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	1.9	36
604	What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness. <i>Blood Research</i> , 2019, 54, 153-156.	0.5	1
605	Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). <i>Clinical Cancer Research</i> , 2019, 25, 6073-6079.	3.2	14
606	Optimal management of mantle cell lymphoma in the primary setting. <i>Expert Review of Hematology</i> , 2019, 12, 715-721.	1.0	0
607	Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 613-626.	0.9	8
608	Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 627-638.	0.9	7
609	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 639-656.	0.9	12
610	Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. <i>British Journal of Haematology</i> , 2019, 187, 364-371.	1.2	11
611	Contemporary management of nodal and primary splenic marginal zone lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 1011-1022.	1.0	2

#	ARTICLE	IF	CITATIONS
612	Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study. <i>Annals of Hematology</i> , 2019, 98, 2729-2737.	0.8	9
613	Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 751-757.	0.2	19
614	<p>Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8003-8014.	1.0	5
615	Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. <i>Cancer Medicine</i> , 2019, 8, 7174-7185.	1.3	13
616	Keeping Our Finger on the Pulse: Reaffirming the Role of Radiation Therapy in the Curative Management of Early Stage Follicular Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 459-465.	0.4	2
619	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 866.	1.3	25
620	Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4417.	1.8	23
622	An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 861.	1.3	1
623	How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2019, 134, 2022-2035.	0.6	65
624	Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e616-e623.	0.2	1
625	What is new in the treatment of Waldenstrom macroglobulinemia?. <i>Leukemia</i> , 2019, 33, 2555-2562.	3.3	19
626	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 13544.	1.6	8
627	How I treat early-relapsing follicular lymphoma. <i>Blood</i> , 2019, 133, 1540-1547.	0.6	33
628	Rituximab, interferon- α 2b and dose denseCVPis highly efficient in patients with FLIPI $\% \hat{A}^2$ follicular lymphoma. Final results of theLNH ϵ PRO \hat{A}^5 study. <i>British Journal of Haematology</i> , 2019, 186, 168-170.	1.2	1
629	Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2019, 60, 573-582.	0.6	11
630	Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e172-e183.	0.2	16
631	Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 300-309.e5.	0.2	5
632	Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach. <i>Current Oncology Reports</i> , 2019, 21, 63.	1.8	6

#	ARTICLE	IF	CITATIONS
633	How I manage patients with follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 513-523.	1.2	9
634	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019, 125, 3378-3389.	2.0	10
635	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL). <i>International Journal of Hematology</i> , 2019, 110, 11-19.	0.7	7
636	Updates in prognostication and treatment of Waldenström's macroglobulinemia. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2019, 12, 179-188.	0.6	8
637	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	0.6	45
638	Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 446-453.	1.8	20
639	One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 467-476.	1.8	6
640	Management of patients with follicular lymphoma treated first line with obinutuzumab. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-11.	0.7	0
641	Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 7193.	1.6	17
642	Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2019, 37, 758-758.	0.8	2
643	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13
644	Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2622-2634.	0.6	13
645	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984158.	1.1	160
646	Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. <i>Rheumatology</i> , 2019, , .	0.9	56
647	GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race. <i>Future Science OA</i> , 2019, 5, FSO375.	0.9	1
648	Long-term overall and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 670-678.	1.2	7
649	Frontline management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 1070-1080.	0.5	8
650	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1495-1506.	1.1	7

#	ARTICLE	IF	CITATIONS
651	Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2255-2263.	0.6	0
652	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. <i>American Journal of Hematology</i> , 2019, 94, 710-725.	2.0	151
653	Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia – an updated meta-analysis. <i>British Journal of Haematology</i> , 2019, 186, 234-242.	1.2	5
654	Acalabrutinib for mantle cell lymphoma. <i>Blood</i> , 2019, 133, 2570-2574.	0.6	19
655	Turning Point in the Treatment of Mantle Cell Lymphoma. <i>Yonago Acta Medica</i> , 2019, 62, 001-007.	0.3	1
656	Lenalidomide plus rituximab (R ²) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. <i>British Journal of Haematology</i> , 2019, 185, 874-882.	1.2	37
657	Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2524-2531.	0.6	4
658	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 984-991.	0.8	183
659	Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab. <i>Journal of Clinical Oncology</i> , 2019, 37, 1151-1153.	0.8	0
660	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019, 185, 480-491.	1.2	26
661	Mantle cell lymphoma and its management: where are we now?. <i>Experimental Hematology and Oncology</i> , 2019, 8, 2.	2.0	28
662	Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 240-253.	1.2	39
663	Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?. <i>Annals of Lymphoma</i> , 2019, 3, 2-2.	4.5	1
664	Front-line therapy in elderly patients with mantle cell lymphoma. <i>Annals of Lymphoma</i> , 0, 3, 8-8.	4.5	2
665	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	2.5	18
666	<p>The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 63-71.	1.2	11
667	Waldenström's macroglobulinemia front line treatment. <i>HemaSphere</i> , 2019, 3, 62-64.	1.2	1
668	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. <i>Current Opinion in Oncology</i> , 2019, 31, 374-379.	1.1	4

#	ARTICLE	IF	CITATIONS
669	Simplified MIPI-B prognostic stratification method can predict the outcome wellâ€”retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China. <i>Medicine (United States)</i> , 2019, 98, e13741.	0.4	5
670	Follicular lymphoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 83.	18.1	148
671	Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years. <i>Leukemia and Lymphoma</i> , 2019, 60, 856-859.	0.6	4
672	Frontline management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 422-433.	0.5	5
673	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. <i>Hematological Oncology</i> , 2019, 37, 117-128.	0.8	15
674	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry^{â€”}. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	0.6	7
675	A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, 138-146.	1.7	37
676	Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. <i>British Journal of Haematology</i> , 2019, 184, 223-231.	1.2	13
677	Maintenance rituximab or observation after frontline treatment with bendamustineâ€”rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
678	Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. <i>Haematologica</i> , 2019, 104, 1202-1208.	1.7	64
679	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 95-102.	0.2	9
680	Bendamustine plus rituximab in newly diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). <i>British Journal of Haematology</i> , 2019, 186, 146-149.	1.2	51
681	Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995â€”2013: Findings from Texas and national SEER areas. <i>Cancer Epidemiology</i> , 2019, 58, 89-97.	0.8	5
682	Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. <i>Cancer</i> , 2019, 125, 1101-1112.	2.0	16
683	Upfront Lenalidomide in Follicular Lymphoma: Time has Come or Not?. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 362-363.	0.3	0
684	Novel treatment approaches and future perspectives in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882051.	1.1	11
685	Acalabrutinib for adults with mantle cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 179-187.	1.3	9
686	Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2019, 94, 266-276.	2.0	68

#	ARTICLE	IF	CITATIONS
687	Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1519-1520.	0.8	1
688	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	0.6	0
689	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	0.6	69
690	Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 833-835.	0.6	4
691	Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. <i>Leukemia and Lymphoma</i> , 2019, 60, 955-963.	0.6	12
692	Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 731-734.	0.5	5
693	Rituximab+Bendamustine (R+Benda) in <scp>MALT</scp> lymphoma complicating primary Sjögren syndrome (<scp>pSS</scp>). <i>British Journal of Haematology</i> , 2019, 184, 472-475.	1.2	12
694	Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody. <i>Leukemia and Lymphoma</i> , 2020, 61, 364-369.	0.6	9
695	M7+FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. <i>British Journal of Haematology</i> , 2020, 188, 259-267.	1.2	40
696	Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 39-46.	0.2	5
698	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
699	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
700	Real-world healthcare resource utilization in patients with indolent non-Hodgkin lymphoma: differences between patients treated with first-line ibrutinib or bendamustine+rituximab. <i>Current Medical Research and Opinion</i> , 2020, 36, 439-444.	0.9	0
701	Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade. <i>Hematological Oncology</i> , 2020, 38, 213-222.	0.8	13
702	Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction. <i>International Journal of Hematology</i> , 2020, 111, 585-590.	0.7	2
703	Outcomes of bendamustine-or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 354-361.	2.0	19
704	Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 117-125.	1.0	9
705	Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results Medicare Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e184-e194.	0.2	4

#	ARTICLE	IF	CITATIONS
706	BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 77-89.	1.0	14
707	First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	1.2	16
708	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
709	Follicular lymphoma: 2020 update on diagnosis and management. <i>American Journal of Hematology</i> , 2020, 95, 316-327.	2.0	140
710	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL). <i>International Journal of Hematology</i> , 2020, 111, 5-15.	0.7	4
711	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	0.8	73
712	Follicular Lymphoma. , 2020, , .		0
713	Mixed Lytic and Blastic Bone Lesions as a Presenting Feature of Waldenström Macroglobulinemia: Case Report and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e87-e91.	0.2	2
714	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	1.2	11
715	Mantle cell lymphoma: a rare cause for a swollen palate. <i>BMJ Case Reports</i> , 2020, 13, e238332.	0.2	2
716	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	2.2	96
717	Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 861-870.	0.9	2
718	Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 983-996.	0.9	0
719	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	2.8	81
720	Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. <i>HemaSphere</i> , 2020, 4, e398.	1.2	7
721	Recent advances in the first-line treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 0, 4, 2-2.	4.5	4
722	Management of Waldenström macroglobulinemia in 2020. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 372-379.	0.9	24
723	First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. <i>Cancers</i> , 2020, 12, 3533.	1.7	4

#	ARTICLE	IF	CITATIONS
724	Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 727-741.	0.9	1
725	Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 871-885.	0.9	4
726	Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 971-982.	0.9	1
727	Precision medicine in follicular lymphoma: Focus on predictive biomarkers. <i>Hematological Oncology</i> , 2020, 38, 625-639.	0.8	4
728	A multicenter, open-label, phase II study of tirabrutinib (ONO/GS4059) in patients with Waldenström's macroglobulinemia. <i>Cancer Science</i> , 2020, 111, 3327-3337.	1.7	60
730	First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 2821-2829.	0.8	7
731	Advances in Classification and Treatment of Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 348-356.	1.0	2
732	Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3486-3494.	2.5	23
733	<p>Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6573-6581.	1.0	10
734	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. <i>Expert Review of Hematology</i> , 2020, 13, 851-869.	1.0	2
735	Options for Chemotherapy and Scoring Response and Relapse. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1115-1131.	0.9	0
736	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?. <i>Medicine (United States)</i> , 2020, 99, e21440.	0.4	1
737	Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. <i>EJHaem</i> , 2020, 1, 170-180.	0.4	0
738	Clinical significance of tryptophan catabolism in follicular lymphoma. <i>Hematological Oncology</i> , 2020, 38, 742-753.	0.8	4
739	Emerging drugs for the treatment of Waldenström macroglobulinemia. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 433-444.	1.0	3
740	The safety of available chemo-free treatments for mantle cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1377-1393.	1.0	3
741	Waldenström Macroglobulinemia — 2020 Update on Management and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S39-S41.	0.2	2
742	Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1029-1045.	1.5	4

#	ARTICLE	IF	CITATIONS
743	Maintenance rituximab in Veterans with follicular lymphoma. <i>Cancer Medicine</i> , 2020, 9, 7537-7547.	1.3	2
744	Treatment of hairy cell leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 1107-1117.	1.0	4
745	A comparison of bendamustine-EAM versus BEAM conditioning for autologous stem cell transplant in lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3529-3531.	0.6	1
746	Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches. <i>Current Oncology Reports</i> , 2020, 22, 113.	1.8	5
747	How do we sequence therapy for marginal zone lymphomas?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 295-305.	0.9	13
748	Zanubrutinib for the treatment of Waldenström Macroglobulinemia. <i>Expert Review of Hematology</i> , 2020, 13, 1303-1310.	1.0	3
749	Subgroup analysis in haematologic malignancies phase III clinical trials: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2635-2644.	1.1	6
750	Management of Older Adults with Mantle Cell Lymphoma. <i>Drugs and Aging</i> , 2020, 37, 469-481.	1.3	4
751	Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms. <i>Hematological Oncology</i> , 2020, 38, 344-352.	0.8	2
752	Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2020, 26, 4216-4224.	3.2	126
753	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
754	Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. <i>Bone Marrow Transplantation</i> , 2020, 55, 2350-2353.	1.3	0
755	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
756	Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. <i>Journal of Medical Case Reports</i> , 2020, 14, 75.	0.4	6
757	Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. <i>Frontiers in Oncology</i> , 2020, 10, 815.	1.3	19
758	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2492-2496.	0.6	0
759	The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 650-660.	1.2	21
760	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	6.9	17

#	ARTICLE	IF	CITATIONS
761	Real-World Budget Impact of Listing a Biosimilar of Rituximab. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	1
762	The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. British Journal of Haematology, 2020, 190, 545-554.	1.2	5
763	Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. PharmacoEconomics - Open, 2020, 4, 575-591.	0.9	4
764	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. International Journal of Cancer, 2020, 147, 1979-1986.	2.3	6
765	Increasing Diluent Volume Decreases Bendamustine-Induced Venous Irritation without Reducing the Therapeutic Efficacy. Biological and Pharmaceutical Bulletin, 2020, 43, 488-492.	0.6	1
766	Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematology, 2020, 7, e295-e308.	2.2	38
767	Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. Hematological Oncology, 2020, 38, 487-492.	0.8	11
768	Treatment of Histologic Transformation. Hematology/Oncology Clinics of North America, 2020, 34, 785-794.	0.9	4
769	Early Progression of Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 757-769.	0.9	2
770	Initial Treatment of High Tumor Burden Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 673-687.	0.9	1
771	Mantle cell lymphoma. Critical Reviews in Oncology/Hematology, 2020, 153, 103038.	2.0	21
772	Immunoglobulin M Paraproteinaemias. Cancers, 2020, 12, 1688.	1.7	15
773	The investigation and management of follicular lymphoma. British Journal of Haematology, 2020, 191, 363-381.	1.2	14
774	Antibody Therapy Maintenance in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 689-699.	0.9	2
775	Advances in Treatment of Follicular Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 231-240.	1.0	5
776	Controversies in the Treatment of Follicular Lymphoma. HemaSphere, 2020, 4, e317.	1.2	15
777	Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Annals of Pharmacotherapy, 2020, 54, 879-898.	0.9	4
778	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	0.8	103

#	ARTICLE	IF	CITATIONS
779	Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. <i>Annals of Hematology</i> , 2020, 99, 1073-1079.	0.8	5
780	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. <i>Leukemia and Lymphoma</i> , 2020, 61, 1380-1387.	0.6	4
781	Mantle cell lymphoma "where precision medicine based on response-adapted treatment strategies could show its full worth. <i>British Journal of Haematology</i> , 2020, 189, 600-602.	1.2	0
782	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020, 55, 1076-1084.	1.3	20
783	Lymphoma in Sjögren's Syndrome: Predictors and Therapeutic Options. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 1-17.	0.6	12
784	Waldenstrom's macroglobulinemia in the era of immunotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1292-1304.	0.6	1
785	Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 31-43.	1.2	9
786	Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 904.	1.8	13
787	An update on options of therapy for aggressive mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2036-2049.	0.6	0
788	Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 431-438.	0.7	7
789	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2020, 105, 1907-1913.	1.7	23
790	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 775-783.	2.0	7
791	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. <i>International Journal of Hematology</i> , 2020, 111, 642-656.	0.7	1
792	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 453-458.	0.2	2
793	EHA evaluation of the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
794	Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. <i>Journal of the Neurological Sciences</i> , 2020, 413, 116777.	0.3	9
795	How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 103-110.	0.1	33
796	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2837-2846.	0.8	9

#	ARTICLE	IF	CITATIONS
797	Safety and Efficacy of Bendamustine-Rituximab in Treatment Na ⁺ ve Symptomatic Follicular Lymphoma: An Institutional Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 169-170.	0.3	1
798	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. <i>Future Oncology</i> , 2021, 17, 255-262.	1.1	13
799	Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016. <i>Leukemia</i> , 2021, 35, 1683-1695.	3.3	8
800	Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 485-493.	1.0	32
801	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 298-308.	0.6	127
802	Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 590-597.	0.6	2
803	Trochlear nerve damage resulting from Waldenstrom's macroglobulinemia: A case report and literature review. <i>Revue Neurologique</i> , 2021, 177, 317-319.	0.6	0
804	Current and Emerging Treatments for Waldenström Macroglobulinemia. <i>Acta Haematologica</i> , 2021, 144, 146-157.	0.7	7
805	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 641-647.	2.8	4
806	Initial report of a phase II study with R-FND followed by ibrutinomab tixetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 58-67.	0.6	2
807	Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. <i>Acta Haematologica</i> , 2021, 144, 322-326.	0.7	0
808	Extended follow-up of CD4 ⁺ T cell recovery kinetics in a large cohort of patients with B-cell lymphoproliferative disease treated with rituximab-bendamustine. <i>Hematological Oncology</i> , 2021, 39, 137-140.	0.8	6
809	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 8-18.	1.2	5
810	How we treat mature B-cell neoplasms (indolent B-cell lymphomas). <i>Journal of Hematology and Oncology</i> , 2021, 14, 5.	6.9	16
811	A brief rituximab, bendamustine, mitoxantrone (R ⁺ BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
812	Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. <i>Journal of Cancer</i> , 2021, 12, 2488-2497.	1.2	3
813	Waldenstrom's Macroglobulinemia. <i>Hematologic Malignancies</i> , 2021, , 143-161.	0.2	3
814	Nodal Marginal Zone Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 117-125.	0.2	0

#	ARTICLE	IF	CITATIONS
815	Blastic Mantle Cell Lymphoma of the Gastroesophageal Junction: A Unique Presentation and Literature Review. <i>Case Reports in Gastroenterology</i> , 2021, 15, 70-79.	0.3	0
816	Follicular Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 67-91.	0.2	0
817	A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 162-167.	0.3	0
818	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma). <i>Hematologic Malignancies</i> , 2021, , 93-115.	0.2	1
819	Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study. <i>Annals of Hematology</i> , 2021, , 1.	0.8	3
820	The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110177.	1.1	3
821	Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkinâ€™s lymphoma. <i>Supportive Care in Cancer</i> , 2021, 29, 5075-5082.	1.0	1
822	Novel Therapy Approaches to Follicular Lymphoma. <i>Drugs</i> , 2021, 81, 453-469.	4.9	4
823	Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103212.	2.0	8
824	Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 4867-4874.	1.0	8
825	Targeted Therapies for Follicular Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 25-31.	1.2	2
826	Survival of patients with marginal zone lymphoma in the <scp>United States:</scp> A populationâ€™based cohort study (2000 to 2017). <i>American Journal of Hematology</i> , 2021, 96, E123-E126.	2.0	9
827	When to Use Targeted Therapy for the Treatment of Follicular Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 45-51.	1.2	3
828	Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis. <i>Cancers</i> , 2021, 13, 630.	1.7	5
829	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. <i>Supportive Care in Cancer</i> , 2021, 29, 5197-5207.	1.0	6
830	Clinical application of genomics in WaldenstrÃ¶m macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1805-1815.	0.6	3
831	Mantle cell lymphoma â€™ advances in molecular biology, prognostication and treatment approaches. <i>British Journal of Haematology</i> , 2021, 195, 162-173.	1.2	31
832	Reducing treatment toxicity in WaldenstrÃ¶m macroglobulinemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	1.0	2

#	ARTICLE	IF	CITATIONS
833	Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 310-327.	1.8	1
834	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology, 2021, 96, 846-853.	2.0	16
835	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances, 2021, 5, 1737-1745.	2.5	4
836	Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning. International Journal of Environmental Research and Public Health, 2021, 18, 2679.	1.2	4
837	Novel immunotherapy in follicular lymphoma: a narrative review. Annals of Lymphoma, 0, 5, 9-9.	4.5	1
838	Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells. Drugs, 2021, 81, 669-684.	4.9	2
839	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. Journal of Personalized Medicine, 2021, 11, 249.	1.1	6
840	Frontline management for follicular lymphoma patients: a narrative review. Annals of Lymphoma, 0, 5, 10-10.	4.5	0
841	Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 139-146.	0.2	6
842	Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. International Journal of Hematology, 2021, 114, 205-216.	0.7	3
843	Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006–2019. Cancers, 2021, 13, 1708.	1.7	1
844	Sjögren's syndrome-associated lymphoma. , 2021, , 205-220.		0
845	Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e423-e427.	0.2	1
846	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncology, 2021, 17, 1269-1283.	1.1	20
847	Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. Advances in Therapy, 2021, 38, 3489-3505.	1.3	2
848	Bendamustine-induced nephrogenic diabetes insipidus – A case report. Journal of Oncology Pharmacy Practice, 2022, 28, 107815522110138.	0.5	2
849	Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. British Journal of Haematology, 2021, 194, 365-377.	1.2	13
850	A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A+B study). British Journal of Haematology, 2021, 193, 1123-1133.	1.2	7

#	ARTICLE	IF	CITATIONS
851	Racial disparities in the survival of patients with indolent <sc>nonâ€Hodgkin</sc> lymphomas in the United States. American Journal of Hematology, 2021, 96, 816-822.	2.0	6
852	Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent Bâ€cell lymphomas. Hematological Oncology, 2021, 39, 465-472.	0.8	1
853	Rare lymphomas in routine practice â€ Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms. Hematological Oncology, 2021, 39, 313-325.	0.8	6
854	Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. Cancer Management and Research, 2021, Volume 13, 3935-3952.	0.9	7
855	Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population. BMC Cancer, 2021, 21, 566.	1.1	1
856	Assessment of fixedâ€duration therapies for treatmentâ€naÃve <sc>WaldenstrÃm</sc> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
857	Real-world data on the survival outcome of patients with newly diagnosed WaldenstrÃm macroglobulinemia. Korean Journal of Internal Medicine, 2021, 36, 668-678.	0.7	2
858	Cellular Therapies for Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 363-370.	0.6	6
859	Management of relapsed follicular lymphoma. Annals of Lymphoma, 0, 5, 14-14.	4.5	4
860	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. Journal of Hematology and Oncology, 2021, 14, 104.	6.9	13
861	Waldenstrom's macroglobulinemia with peripheral neuropathy and favorable long-term treatment responses. Medicine, Case Reports and Study Protocols, 2021, 2, e0111.	0.0	0
862	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer, 2021, 127, 3390-3402.	2.0	6
863	Mantle cell lymphomaâ€Advances in molecular biology, prognostication and treatment approaches. Hematological Oncology, 2021, 39, 31-38.	0.8	8
864	Reduced bendamustine for elderly patients with follicular lymphoma. Annals of Hematology, 2021, , 1.	0.8	1
865	Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies. Oncology and Therapy, 2021, 9, 329-346.	1.0	7
866	Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 55-66.	1.2	2
867	Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkinâ€™s lymphoma. Leukemia and Lymphoma, 2021, 62, 1-9.	0.6	2
868	Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma. Expert Review of Hematology, 2021, 14, 655-668.	1.0	1

#	ARTICLE	IF	CITATIONS
869	Managing complications secondary to Waldenström's macroglobulinemia. Expert Review of Hematology, 2021, 14, 1-12.	1.0	0
870	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	1.7	11
871	Primary follicular lymphoma of colon: A case series and review of literature. Clinical Case Reports (discontinued), 2021, 9, e04486.	0.2	3
872	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation. Expert Opinion on Drug Safety, 2021, 20, 987-995.	1.0	4
873	How to Sequence Therapies in Waldenström Macroglobulinemia. Current Treatment Options in Oncology, 2021, 22, 92.	1.3	5
874	Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma. Journal of Nuclear Medicine, 2021, , jnumed.121.262324.	2.8	2
875	Risk-tailored treatment of splenic marginal zone lymphoma. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	0
876	Two rare cases of bronchus-associated lymphoid tissue lymphoma successfully treated with rituximab-bendamustine. Clinical Case Reports (discontinued), 2021, 9, e04557.	0.2	0
877	Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis. Leukemia Research, 2021, 108, 106605.	0.4	1
878	An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 3809-3820.	2.0	2
879	Follicular lymphoma and macrophages: impact of approved and novel therapies. Blood Advances, 2021, 5, 4303-4312.	2.5	5
880	Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review. Journal of Oncology Pharmacy Practice, 2021, 27, 1993-1999.	0.5	2
881	CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab. Leukemia and Lymphoma, 2022, 63, 31-42.	0.6	5
882	How I treat and prevent venous thrombotic complications in patients with lymphoma. Blood, 2022, 139, 1489-1500.	0.6	5
883	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenström macroglobulinemia. Leukemia, 2022, 36, 532-539.	3.3	50
884	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma. Expert Review of Hematology, 2021, 14, 1-17.	1.0	2
885	Clinical features and treatment of gastric MALT lymphoma. Tenri Medical Bulletin, 2021, 24, 49-62.	0.1	0
886	A medicare database analysis of practice patterns in patients with mantle cell lymphoma. Journal of Geriatric Oncology, 2021, 12, 894-901.	0.5	3

#	ARTICLE	IF	CITATIONS
887	Mantle Cell Lymphoma. Hematologic Malignancies, 2021, , 163-178.	0.2	0
888	Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2021, 96, 258-269.	2.0	49
889	Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 149-179.	0.1	2
890	A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leukemia and Lymphoma, 2018, 59, 2580-2587.	0.6	18
891	Optimizing therapy for mantle cell lymphoma. Hematology American Society of Hematology Education Program, 2017, 2017, 304-309.	0.9	3
892	What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances, 2017, 1, 2486-2490.	2.5	5
893	Molecular profiling and management of mantle cell lymphoma. Hematology American Society of Hematology Education Program, 2019, 2019, 30-40.	0.9	6
894	Lymphoma Therapy and Adverse Events: Nursing Strategies for Thinking Critically and Acting Decisively. Clinical Journal of Oncology Nursing, 2017, 21, 2-12.	0.3	3
895	Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm. Clinical Journal of Oncology Nursing, 2017, 21, 53-59.	0.3	5
896	A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL). American Journal of Case Reports, 2018, 19, 1135-1139.	0.3	4
897	Relevance on the diagnosis of malignant lymphoma of the salivary gland. World Journal of Clinical Cases, 2020, 8, 2717-2726.	0.3	3
898	Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. PLoS ONE, 2014, 9, e90675.	1.1	25
899	Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients. PLoS ONE, 2014, 9, e104004.	1.1	35
900	Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy. Journal of Clinical Medicine Research, 2014, 6, 252-60.	0.6	16
901	Primary Large B-Cell Lymphoma of the Base of Tongue. Journal of Otolaryngology-ENT Research, 2015, 3, .	0.1	1
902	How I treat elderly patients with plasma cell dyscrasias. Aging, 2018, 10, 4248-4268.	1.4	9
903	Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in <i>in vivo</i> and <i>in vitro</i> models of mantle cell lymphoma. Oncotarget, 2014, 5, 726-739.	0.8	25
904	Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex. Oncotarget, 2017, 8, 80223-80234.	0.8	36

#	ARTICLE	IF	CITATIONS
905	Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta analysis. <i>Oncotarget</i> , 2017, 8, 91238-91247.	0.8	3
906	90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. <i>Oncotarget</i> , 2016, 7, 7597-7609.	0.8	31
907	Scientific rationale for immunotherapy in lymphoma and predictors of response. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	2
908	Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice. <i>Klinicheskiya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 65-72.	0.1	1
909	Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis. <i>Internal Medicine</i> , 2017, 56, 847-851.	0.3	4
910	Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 213-223.	1.0	6
911	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.1	4
913	Refractory mantle cell lymphoma in elderly patient - case report. <i>Onkologie (Czech Republic)</i> , 2017, 11, 149-153.	0.0	1
914	Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience. <i>Radiation Oncology Journal</i> , 2015, 33, 310.	0.7	4
915	Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells. <i>Oncology Letters</i> , 2017, 14, 792-800.	0.8	9
916	Individualized management of follicular lymphoma. <i>Chinese Clinical Oncology</i> , 2015, 4, 7.	0.4	7
917	Diagnosis and treatment of mantle cell lymphoma. <i>Swiss Medical Weekly</i> , 2013, 143, w13868.	0.8	4
918	Diagnosis and treatment of follicular lymphoma: an update. <i>Swiss Medical Weekly</i> , 2018, 148, w14635.	0.8	12
919	Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. <i>Drugs in Context</i> , 2020, 9, 1-12.	1.0	6
920	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. <i>Cancers</i> , 2021, 13, 5181.	1.7	13
921	Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas. <i>Current Treatment Options in Oncology</i> , 2021, 22, 111.	1.3	6
922	A single-center analysis of patients with extranodal marginal zone lymphoma of the breast. <i>Leukemia and Lymphoma</i> , 2022, 63, 591-598.	0.6	2
923	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9

#	ARTICLE	IF	CITATIONS
924	Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. British Journal of Haematology, 2022, 196, 660-669.	1.2	7
925	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2012, , 403-445.		0
926	Lymphoma, Non-Hodgkin's. , 2014, , .		0
927	Waldenström's Macroglobulinemia. , 2014, , 303-329.		0
928	Mantle Cell Lymphoma. , 2014, , 277-302.		0
929	Bendamustine in mantle cell lymphoma. Drugs and Cell Therapies in Hematology, 2014, 3, 30.	0.1	0
930	The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. , 2015, , 143-168.		0
931	New Treatment Options in Mantle Cell Lymphoma. European Oncology and Haematology, 2015, 11, 134.	0.0	0
933	Mantle Cell Lymphoma: Current Concepts. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	0
934	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
937	Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence?. Vojnosanitetski Pregled, 2016, 73, 1072-1075.	0.1	3
939	Therapie der indolenten Non-Hodgkin-Lymphome. , 2016, , 31-41.		0
940	Treatment of B-cell lymphomas. , 2016, , 45-57.		0
941	REFRACTORY FOLLICULAR LYMPHOMA AND SHORT-TERM PATIENTS SURVIVAL IN THE ERA OF TARGETED TREATMENT. WHAT IS THE REASON?. , 2016, 15, 79-86.	0.3	0
942	Follicular lymphoma. , 2017, , 75-96.		0
943	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2017, , 437-484.		0
944	Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten. , 2017, , 1-7.		0
945	Lymphoplasmacytic lymphoma in the era of next generation sequencing. , 2017, , 97-109.		0

#	ARTICLE	IF	CITATIONS
946	COMPARISON IMMUNOCHEMOTHERAPY AND CHEMOTHERAPY EFFICASY IN FOLLICULAR LYMPHOMA. , 2017, 16, 24-31.	0.3	0
947	Non-Hodgkin Lymphoma. , 2017, , .		2
948	NonHodgkin lymphomas in elderly patients. Onkologie (Czech Republic), 2017, 11, 128-133.	0.0	0
949	Monoclonal IgM Gammopathy and Waldenstr�m's Macroglobulinemia. Deutsches Ärzteblatt International, 2017, 114, 745-751.	0.6	10
950	Mantle Cell Lymphoma Relapsing as Disease of Skin, Orbit and CNS: An Extremely Rare Presentation and a Review of Literature. Journal of Hematology (Brossard, Quebec), 2018, 7, 38-42.	0.4	3
951	Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten. , 2018, , 241-247.		0
952	Old Dog, New Tricks: Targeting CD20 in B Cell Non-Hodgkin Lymphomas. , 2018, 15, .		0
953	Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients. , 2018, , 1-15.		0
954	Recent Advances in Therapeutics for B-Cell Lymphoma. Journal of Pharmacy and Pharmacology, 2018, 6, .	0.1	0
955	Effectiveness of the Initial Escalation of Immunochemotherapy in Patients with High Risk MALT-Lymphoma: Pilot Study Results. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 338-348.	0.1	0
956	Current Therapeutic Options in Waldenstr�m Macroglobulinemia. Oncology & Hematology Review, 2019, 15, 39.	0.2	0
957	Follicular lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 214.	0.3	2
958	Mantle cell lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 226.	0.3	1
959	The Impact of First Complete Remission by PET-CT and Time to Next Treatment on Survival of Follicular Lymphoma Patients. Clinical Hematology International, 2019, 1, 168-172.	0.7	0
960	Gastrointestinal Lymphomas. , 2019, , 329-349.		0
961	Sensorineural hearing loss in a patient with follicular lymphoma treated with bendamustine and rituximab. Annals of Lymphoma, 0, 3, 5-5.	4.5	0
963	Molecular Targeting in Follicular Lymphoma. , 2020, , 207-218.		0
964	Current Management and Novel Approaches to the Management of Follicular Lymphoma. , 2020, , 119-134.		0

#	ARTICLE	IF	CITATIONS
965	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2020, , 463-512.		0
966	Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management. Journal of the Advanced Practitioner in Oncology, 2020, 11, 381-389.	0.2	2
967	Mantle Cell Lymphoma: History, Current Principles of Diagnosis, and Treatment (Literature Review). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 366-381.	0.1	0
968	Follicular Lymphoma: Therapeutics and Management. Molecular and Translational Medicine, 2020, , 149-162.	0.4	0
969	Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1761-1763.	2.3	0
970	Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients. , 2020, , 567-581.		0
971	Novel Therapeutics in the Management of Waldenström Macroglobulinemia. , 2020, , 15-26.		0
972	Mantle Cell Lymphoma: Therapeutics and Management. Molecular and Translational Medicine, 2020, , 163-177.	0.4	0
973	Therapy Response Imaging in Lymphoma and Hematologic Malignancies. Medical Radiology, 2020, , 177-200.	0.0	0
974	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
975	Bendamustine plus rituximab: is it a BRIGHT idea?. Chinese Clinical Oncology, 2020, 9, 22-22.	0.4	0
976	Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood, 2022, 139, 666-677.	0.6	27
977	Conditional relative survival in Waldenström's macroglobulinaemia: a population-based study in The Netherlands. British Journal of Haematology, 2021, , .	1.2	2
978	G protein nucleolar 3 promotes Non-Hodgkin lymphoma progression by activating the Wnt/ β -catenin signaling pathway. Experimental Cell Research, 2021, 409, 112911.	1.2	1
980	Experience with the use of bendamustine (Rozustin®): safety and efficacy. Oncogematologiya, 2020, 15, 27-37.	0.1	0
981	Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma. Biological and Pharmaceutical Bulletin, 2020, 43, 1577-1582.	0.6	3
982	Concurrent Incidental Presentation of Primary Retroperitoneal Follicular Lymphoma With Acute Pancreatitis. Cureus, 2020, 12, e11687.	0.2	0
983	Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19. Revista Colombiana De Cancerología, 0, 24, .	0.0	2

#	ARTICLE	IF	CITATIONS
984	Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders. Iranian Journal of Pediatric Hematology and Oncology, 2013, 3, 125-34.	0.4	0
986	Follicular lymphoma: an Institutional Analysis. Asian Pacific Journal of Cancer Prevention, 2017, 18, 681-685.	0.5	5
987	Mantle Cell Lymphoma: An Evolving Therapeutic Landscape. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 50S-53S.	0.6	0
988	Real-World Budget Impact of Listing a Biosimilar of Rituximab. Canadian Journal of Hospital Pharmacy, 2020, 73, 13-18.	0.1	2
995	Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases. Croatian Medical Journal, 2021, 62, 455-463.	0.2	2
996	Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. Current Problems in Cancer, 2022, 46, 100813.	1.0	3
997	Decreased expression of Tâ€cellâ€associated immune markers predicts poor prognosis in patients with follicular lymphoma. Cancer Science, 2021, , .	1.7	5
998	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. Cancer Reports, 2021, , e1590.	0.6	3
999	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2022, 40, 202-212.	0.8	34
1000	Early Progressing Follicular Lymphoma. Current Oncology Reports, 2021, 23, 149.	1.8	2
1001	Sequencing of Novel Therapies for Mantle Cell Lymphoma. Current Treatment Options in Oncology, 2021, 22, 118.	1.3	3
1002	Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 62, .	0.3	1
1003	Managing Relapsed Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	2
1004	Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study. Frontiers in Oncology, 2021, 11, 770988.	1.3	3
1005	Time for an individualized approach to first-line management of follicular lymphoma. Haematologica, 2022, 107, 7-18.	1.7	13
1006	Difference of compliance rates for the recommendations in Japanese Guideline on Febrile Neutropenia according to respondentsâ€™ attributes: the second report on a questionnaire survey among hematology-oncology physicians and surgeons. Supportive Care in Cancer, 2022, 30, 4327.	1.0	0
1007	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Folldela Study. Cancers, 2022, 14, 654.	1.7	3
1008	Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. Frontiers in Pharmacology, 2022, 13, 788824.	1.6	1

#	ARTICLE	IF	CITATIONS
1009	Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study. <i>Oncologist</i> , 2022, 27, 532-e542.	1.9	3
1010	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. <i>Blood Cancer Journal</i> , 2022, 12, 1.	2.8	7
1011	Diagnosis and management of Waldenström macroglobulinaemia: A British Society for Haematology guideline. <i>British Journal of Haematology</i> , 2022, 197, 171-187.	1.2	30
1012	Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of β 2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	0.7	0
1013	Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine. <i>Frontiers in Immunology</i> , 2021, 12, 798251.	2.2	1
1014	Hematopoietic cell transplantation for mantle cell lymphoma. <i>International Journal of Hematology</i> , 2022, 115, 301.	0.7	0
1015	Marginal zone lymphoma: present status and future perspectives. <i>Haematologica</i> , 2022, 107, 35-43.	1.7	22
1016	Current approach to Waldenström Macroglobulinemia. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100527.	0.7	8
1017	Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, 62, 91-98.	0.3	1
1018	90 yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. <i>Annals of Hematology</i> , 2022, 101, 781-788.	0.8	6
1019	The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. <i>Pharmaceuticals</i> , 2022, 15, 207.	1.7	5
1022	Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases. <i>Croatian Medical Journal</i> , 2021, 62, 455-463.	0.2	1
1023	Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 73.	0.1	0
1024	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	7
1025	Navigating the Treatment Landscape of Advanced Follicular Lymphoma: Should You Consider a CAR, and Which Model?. , 2022, 19, .		0
1026	Follicular Lymphoma: a Focus on Current and Emerging Therapies. <i>Oncology</i> , 2022, , .	0.4	10
1027	BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis. <i>Journal of Chemotherapy</i> , 2022, , 1-10.	0.7	1
1028	CAR T-cell therapy for B-cell lymphoma. <i>Current Problems in Cancer</i> , 2022, 46, 100826.	1.0	26

#	ARTICLE	IF	CITATIONS
1029	Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab. <i>Hematology</i> , 2022, 27, 384-395.	0.7	2
1030	Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor â€” a retrospective, single center study. <i>Leukemia and Lymphoma</i> , 2022, , 1-8.	0.6	1
1031	Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 5659-5667.	2.5	3
1032	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. <i>Blood Advances</i> , 2022, 6, 3339-3342.	2.5	5
1033	Multi-catalytic Sites Inhibition of Bcl2 Induces Expanding of Hydrophobic Groove: A New Avenue Towards WaldenstrÃ¶m Macroglobulinemia Therapy. <i>Protein Journal</i> , 2022, 41, 201-215.	0.7	2
1034	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	0.6	56
1035	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
1036	Mantle cell lymphoma in 2022â€”A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. <i>American Journal of Hematology</i> , 2022, 97, 638-656.	2.0	48
1037	Inflammatory WaldenstrÃ¶m's macroglobulinaemia: A French monocentric retrospective study of 67 patients. <i>British Journal of Haematology</i> , 2022, 197, 728-735.	1.2	3
1038	When a Monoclonal Gammopathy Is Not Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 655-664.	1.8	2
1039	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
1040	Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen â€” a real world study on patients diagnosed in Sweden 2007-2017. <i>Haematologica</i> , 2022, 107, 740-743.	1.7	9
1041	Follicular Lymphoma. , 0, , .		1
1042	Multimodal Imaging of WaldenstrÃ¶m Macroglobulinemia-Associated Hyperviscosity-Related Retinopathy Treated with Plasmapheresis. <i>Case Reports in Ophthalmological Medicine</i> , 2021, 2021, 1-5.	0.3	3
1043	Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. <i>Cancers</i> , 2021, 13, 6089.	1.7	10
1044	SAMHD1 Mutations and Expression in Mantle Cell Lymphoma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 763151.	1.3	9
1045	Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5285-5294.	2.5	7
1046	Management of elderly patients with malignant lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 690-699.	0.6	2

#	ARTICLE	IF	CITATIONS
1054	Mantle cell lymphoma-management in evolution. Chinese Clinical Oncology, 2015, 4, 8.	0.4	0
1055	Follicular Lymphoma: a Focus on Current and Emerging Therapies.. Oncology, 2022, 36, 97-106.	0.4	9
1056	Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. Leukemia Research Reports, 2022, 17, 100319.	0.2	0
1057	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. Therapeutic Advances in Hematology, 2022, 13, 204062072210939.	1.1	4
1058	The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia. Journal of Personalized Medicine, 2022, 12, 676.	1.1	0
1059	Treatment of indolent lymphoma. Blood Research, 2022, 57, S120-S129.	0.5	2
1060	Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study. Frontiers in Oncology, 2022, 12, .	1.3	1
1061	SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Advances, 2022, 6, 3911-3920.	2.5	4
1062	Bendamustine: a review of pharmacology, clinical use and immunological effects (Review). Oncology Reports, 2022, 47, .	1.2	12
1063	New Directions for Mantle Cell Lymphoma in 2022. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 614-628.	1.8	14
1065	Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group. International Journal of Hematology, 2022, 115, 811-815.	0.7	1
1066	The role of surveillance computed tomography in patients with follicular lymphoma. Therapeutic Advances in Hematology, 2022, 13, 204062072210959.	1.1	1
1067	Marked Response to Chemoimmunotherapy in a Patient with Follicular Lymphoma of Huge Mesenteric Lymphadenopathy. Journal of Cancer Research and Practice, 2022, 9, 77.	0.2	0
1068	Immunotherapy in indolent Non-Hodgkin's Lymphoma. Leukemia Research Reports, 2022, 17, 100325.	0.2	0
1069	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology, 2023, 41, 555-567.	0.8	82
1070	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 2482-2494.	13.9	83
1071	Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives. Cancers, 2022, 14, 3019.	1.7	7
1072	Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual. Journal of Clinical Oncology, 2022, 40, 2600-2608.	0.8	3

#	ARTICLE	IF	CITATIONS
1073	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). <i>HemaSphere</i> , 2022, 6, e745.	1.2	7
1074	Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 657-668.	0.9	3
1075	Current and Future Therapies for Marginal Zone Lymphoma. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 40.	0.1	0
1076	The impact of sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
1077	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	0.8	23
1078	Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2495-2506.	13.9	44
1079	Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1883-1893.	1.2	2
1080	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. <i>Blood</i> , 2022, 140, 1907-1916.	0.6	22
1081	Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-cell Non-Hodgkin's Lymphoma. <i>Clinical Pharmacology in Drug Development</i> , 0, , .	0.8	0
1082	Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline. <i>HemaSphere</i> , 2022, 6, e746.	1.2	0
1083	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 903-914.	1.1	1
1084	A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 83-95.	1.1	1
1085	Hematologic Malignancy: The Lymphomas. , 2023, , 529-554.		0
1086	IV. Pathogenesis, Diagnosis, and Therapeutic Management of Follicular Lymphoma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 1411-1417.	0.0	0
1087	Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study. <i>Annals of Hematology</i> , 0, , .	0.8	0
1088	A Focus on Waldenström Macroglobulinemia and AL Amyloidosis. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 45-56.	0.2	0
1089	Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 107-117.	1.2	5
1090	The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the <sc>SEER</sc> database in the context of evolving disease classification and treatment. <i>British Journal of Haematology</i> , 2022, 199, 696-706.	1.2	3

#	ARTICLE	IF	CITATIONS
1091	A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 99-106.	1.2	2
1092	Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis. World Journal of Gastrointestinal Oncology, 2022, 14, 1552-1561.	0.8	0
1093	Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study <scp>MabScale</scp>. Cancer Medicine, 2023, 12, 2739-2751.	1.3	2
1094	Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Global Oncology, 2022, , .	0.8	3
1095	Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
1096	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e1019-e1031.	0.2	7
1097	Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Leukemia and Lymphoma, 2022, 63, 2889-2896.	0.6	1
1098	The Clinical Impact of Precisely Defining Mantle Cell Lymphoma: Contributions of Elaine Jaffe. Hemato, 2022, 3, 508-517.	0.2	0
1099	Follicular lymphoma: 2023 update on diagnosis and management. American Journal of Hematology, 2022, 97, 1638-1651.	2.0	22
1100	Shining a Light on a Randomized Trial: Ibrutinib Plus Rituximab and Bendamustine in Untreated Mantle Cell Lymphoma. , 2022, 19, .		0
1101	Ibrutinib-rituximab in Waldenström's macroglobulinemia. Cancer Research Statistics and Treatment, 2022, 5, 351.	0.1	0
1102	A roadmap for clinical trial design in marginal zone lymphoma. American Journal of Hematology, 2022, 97, 1398-1403.	2.0	1
1103	Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis. Journal of Oncology, 2022, 2022, 1-12.	0.6	1
1104	Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide. Journal of Clinical Oncology, 0, , .	0.8	1
1105	EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer, 2022, 22, .	1.1	8
1106	Clinical utility of interim CT scans in patients receiving chemoimmunotherapy for first line treatment of follicular lymphoma. Leukemia and Lymphoma, 0, , 1-7.	0.6	1
1107	A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia. Current Oncology, 2022, 29, 7122-7139.	0.9	0
1109	First-Line Treatment of Waldenström's Macroglobulinaemia: Considerations Based on the Dutch National Guideline. Hemato, 2022, 3, 704-717.	0.2	0

#	ARTICLE	IF	CITATIONS
1110	Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience. <i>Leukemia and Lymphoma</i> , 0, , 1-7.	0.6	0
1111	Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?. <i>Hemato</i> , 2022, 3, 689-703.	0.2	0
1112	Waldenström's macroglobulinemia, overview of clinical symptoms, and therapy and our experience with ibrutinib therapy. <i>Onkologie (Czech Republic)</i> , 2022, 16, 83-102.	0.0	0
1113	Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. <i>Blood Advances</i> , 2023, 7, 1606-1614.	2.5	1
1114	Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma. <i>Annals of Hematology</i> , 0, , .	0.8	0
1115	Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study. <i>Investigational New Drugs</i> , 2023, 41, 1-12.	1.2	1
1116	Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. <i>HemaSphere</i> , 2022, 6, e807.	1.2	1
1117	CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211421.	1.1	5
1118	Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 0, , .	0.5	0
1119	Divergent paths: management of early relapsed follicular lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 666-675.	0.9	0
1120	Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis. <i>Anticancer Research</i> , 2022, 42, 6083-6089.	0.5	2
1121	Nodal marjinal zon lenfomada rituksimab-bendamustin sonrası rituksimab lizis sendromu. <i>Ege Tıp Dergisi</i> , 0, , 674-674.	0.1	0
1122	Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020. <i>British Journal of Haematology</i> , 2023, 201, 64-74.	1.2	5
1123	Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study. <i>International Journal of Cancer</i> , 2023, 152, 1884-1893.	2.3	2
1124	Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2023, 98, 348-358.	2.0	9
1125	Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6 Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma. <i>Modern Pathology</i> , 2023, , 100043.	2.9	0
1126	Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. <i>Cancer Treatment Reviews</i> , 2023, 113, 102510.	3.4	1
1127	A rare case report of waldenström macroglobulinemia converted to serum low IgM. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
1128	Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1129	Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1130	Lymphoplasmacytic lymphoma with IgG- κ paraproteinemia presenting as a hepatic bulky mass. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, 62, 273-278.	0.3	0
1131	Treatment approaches for patients with TP53-mutated mantle cell lymphoma. <i>Lancet Haematology</i> , the, 2023, 10, e142-e154.	2.2	6
1132	Management of Marginal Zone Lymphoma: A Canadian Perspective. <i>Current Oncology</i> , 2023, 30, 1745-1759.	0.9	0
1133	Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter study. <i>Biomarker Research</i> , 2023, 11, .	2.8	3
1134	Body Composition in Patients with Follicular Lymphoma: Associations between Changes in Radiomic Parameters in Patients Treated with R-CHOP-like and R-B Regimens: LyRa 01F. <i>Cancers</i> , 2023, 15, 999.	1.7	1
1135	Personalized approaches for treatment-naïve mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2023, 16, 95-107.	1.0	0
1136	Follicular lymphoma: an update on biology and optimal therapy. <i>Leukemia and Lymphoma</i> , 2023, 64, 761-775.	0.6	1
1137	Achieving the cure of follicular lymphoma: is it time to finalize treatment strategies to reach this goal in a subset of patients?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2023, 15, e2023018.	0.5	1
1138	Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing. <i>American Journal of Hematology</i> , 2023, 98, 750-759.	2.0	3
1139	Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle cell lymphoma ineligible for intensive therapy: A network meta-analysis. <i>European Journal of Haematology</i> , 0, , .	1.1	0
1140	Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials. <i>Seminars in Hematology</i> , 2023, , .	1.8	0
1141	Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. <i>Seminars in Hematology</i> , 2023, 60, 73-79.	1.8	6
1142	CAR T-Cell therapy for the management of mantle cell lymphoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	11
1143	Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. <i>Blood Advances</i> , 2023, 7, 4518-4527.	2.5	2
1144	Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes. <i>Cancer Management and Research</i> , 0, Volume 15, 367-375.	0.9	1
1146	Primary Gastric Lymphoma. , 2023, , 507-515.		0

#	ARTICLE	IF	CITATIONS
1147	Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma. Expert Review of Hematology, 2023, 16, 333-348.	1.0	0
1170	Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Annals of Hematology, 0, , .	0.8	1
1176	Stem Cell Transplant for B Cell Non-Hodgkin Lymphoma. , 2023, , 283-334.		0
1191	Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy. , 2024, , 103-122.		0
1192	Targeted therapies for follicular lymphoma. , 2024, , 123-145.		0
1217	Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs, 0, , .	4.9	1
1221	Mantelzelllymphom. , 2023, , 179-196.		0
1222	Extranodales Marginalzonenlymphom des mukosaassoziierten lymphatischen Gewebes (MALT-Lymphom). , 2023, , 103-128.		0
1223	Nodales Marginalzonenlymphom. , 2023, , 129-137.		0
1224	Folikuläres Lymphom. , 2023, , 75-102.		0
1225	Waldenström-Makroglobulinämie. , 2023, , 157-177.		0
1226	Mantle Cell Lymphoma. , 2023, , .		0
1230	Waldenstrom Macroglobulinemia. , 2024, , .		0
1231	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2024, , 491-544.		0